ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Adalimumab (including biosimilars): Pediatric drug information

Adalimumab (including biosimilars): Pediatric drug information
(For additional information see "Adalimumab (including biosimilars): Drug information" and see "Adalimumab (including biosimilars): Patient drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
ALERT: US Boxed Warning
Serious infections:

Patients treated with adalimumab are at increased risk of developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants, such as methotrexate or corticosteroids.

Discontinue adalimumab if a patient develops a serious infection or sepsis. Reported infections include the following:

Active tuberculosis (TB), including reactivation of latent TB. Patients with TB frequently have presented with disseminated or extrapulmonary disease. Test patients for latent TB before adalimumab use and during therapy. Initiate treatment for latent infection prior to adalimumab use.

Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric antifungal therapy in patients at risk of invasive fungal infections who develop severe systemic illness.

Bacterial, viral, and other infections caused by opportunistic pathogens, including Legionella and Listeria.

Carefully consider the risks and benefits of treatment with adalimumab prior to initiating therapy in patients with chronic or recurrent infection.

Monitor patients closely for the development of signs and symptoms of infection during and after treatment with adalimumab, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.

Malignancy:

Lymphoma and other malignancies, some fatal, have been reported in children and adolescents treated with tumor necrosis factor (TNF)–blockers, including adalimumab. Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF-blockers, including adalimumab. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF-blocker cases have occurred in patients with Crohn disease or ulcerative colitis and the majority were in adolescent and young adult males. Almost all these patients had received treatment with azathioprine or 6-mercaptopurine concomitantly with a TNF-blocker at or prior to diagnosis. It is uncertain whether the occurrence of HSTCL is related to use of a TNF-blocker or a TNF-blocker in combination with these other immunosuppressants.

Brand Names: US
  • Abrilada;
  • Amjevita;
  • Cyltezo;
  • Cyltezo-CD/UC/HS Starter;
  • Cyltezo-Psoriasis Starter;
  • Hadlima;
  • Hadlima PushTouch;
  • Hulio;
  • Humira;
  • Humira Pediatric Crohns Start;
  • Humira Pen;
  • Humira Pen-CD/UC/HS Starter;
  • Humira Pen-Pediatric UC Start;
  • Humira Pen-Ps/UV/Adol HS Start;
  • Humira Pen-Psor/Uveit Starter;
  • Hyrimoz;
  • Hyrimoz-Crohns/UC Starter;
  • Hyrimoz-Plaque Psoriasis Start;
  • Idacio;
  • Idacio for Crohns Disease/UC;
  • Idacio for Plaque Psoriasis;
  • Yuflyma;
  • Yuflyma 1-Pen Kit;
  • Yuflyma 2-Pen Kit;
  • Yuflyma 2-Syringe Kit;
  • Yuflyma-CD/UC/HS Starter;
  • Yusimry
Brand Names: Canada
  • Abrilada;
  • Amgevita;
  • Amgevita SureClick;
  • Hadlima;
  • Hadlima PushTouch;
  • Hulio;
  • Humira;
  • Hyrimoz;
  • Idacio;
  • Simlandi;
  • Yuflyma
Therapeutic Category
  • Antirheumatic, Disease Modifying;
  • Gastrointestinal Agent, Miscellaneous;
  • Monoclonal Antibody;
  • Tumor Necrosis Factor (TNF) Blocking Agent
Dosing: Pediatric

Dosage guidance:

Dosage form information: In the United States, Amjevita (adalimumab-atto) has been approved as a biosimilar to Humira (adalimumab). In Canada, Abrilada, Amgevita, Hadlima, Hulio, Hyrimoz, Idacio, Simlandi, and Yuflyma are also approved as biosimilars to Humira; refer to Canadian product monograph(s) for biosimilar-specific indication details. Approved ages and uses may vary (consult product labeling).

Crohn disease, moderate to severe

Crohn disease, moderate to severe:

Children ≥6 years and Adolescents:

17 kg to <40 kg: SUBQ:

Initial: 80 mg on day 1, then 40 mg administered 2 weeks later (day 15).

Maintenance (beginning day 29): 20 mg every other week (Ref). Patients who continue to experience flares after 12 weeks of therapy may benefit from weekly dosing (Ref).

≥40 kg: SUBQ:

Initial: 160 mg (administered on day 1 or split and administered over 2 consecutive days), then 80 mg administered 2 weeks later (day 15).

Maintenance (beginning day 29): 40 mg every other week (Ref). Weekly dosing should be considered for patients with loss of response or low trough concentrations (<7.5 mcg/mL) (Ref).

Hidradenitis suppurativa

Hidradenitis suppurativa:

Children ≥12 years and Adolescents:

30 to <60 kg: SUBQ:

Initial: 80 mg on day 1.

Maintenance (beginning day 8): 40 mg every other week.

≥60 kg: SUBQ:

Initial: 160 mg (administered as full dose on day 1 or dose split and administered over 2 consecutive days), then 80 mg 2 weeks later (day 15).

Maintenance (beginning day 29): 40 mg weekly or 80 mg every other week.

Juvenile idiopathic arthritis

Juvenile idiopathic arthritis (JIA):

Fixed dosing:

Children ≥2 years and Adolescents:

10 kg to <15 kg: SUBQ: 10 mg every other week.

15 to <30 kg: SUBQ: 20 mg every other week.

≥30 kg: SUBQ: 40 mg every other week.

BSA-directed dosing: Note: Dosing based on trials performed with Humira product.

Children 2 to <4 years: SUBQ: 24 mg/m2/dose every other week; maximum dose: 20 mg/dose (Ref).

Children and Adolescents 4 to 17 years: SUBQ: 24 mg/m2/dose every other week; maximum dose: 40 mg/dose (Ref).

Ulcerative colitis; moderate to severe

Ulcerative colitis; moderate to severe:

Fixed dosing: Children ≥5 years and Adolescents:

20 to <40 kg: SUBQ:

Initial: 80 mg on day 1, then 40 mg administered weekly for 2 weeks (a dose on day 8 and day 15).

Maintenance (beginning day 29): 40 mg every other week or 20 mg every week.

≥40 kg: SUBQ:

Initial: 160 mg on day 1 (administered as full dose on day 1 or dose split and administered over 2 consecutive days), then 80 mg administered weekly for 2 weeks (a dose on day 8 and day 15).

Maintenance (beginning day 29): 80 mg every other week or 40 mg every week.

BSA-directed dosing: Children and Adolescents: SUBQ: Initial: 92 mg/m2 (maximum dose: 160 mg/dose), then 46 mg/m2 (maximum dose: 80 mg/dose) 2 weeks later, then on day 29, begin maintenance therapy: 23 mg/m2 every other week (maximum dose: 40 mg/dose) (Ref). Note: Trials performed with Humira product.

Uveitis

Uveitis (noninfectious intermediate, posterior, and panuveitis):

Fixed dosing: Children ≥2 years and Adolescents:

10 kg to <15 kg: SUBQ: 10 mg every other week.

15 to <30 kg: SUBQ: 20 mg every other week.

≥30 kg: SUBQ: 40 mg every other week.

BSA-directed dosing: Children ≥4 years and Adolescents: SUBQ: 24 or 40 mg/m2/dose every 2 weeks; maximum dose 40 mg/dose (Ref). Dosing based on one prospective trial comparing 24 mg/m2/dose every 2 weeks of adalimumab (n=16, ages 6 to 12 years) to infliximab (n=17, ages 5 to 13 years) and on a retrospective trial of biologic response modifiers, including 5 patients who received adalimumab at 40 mg/m2/dose every 2 weeks. Note: Trials performed with Humira product.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Adult

(For additional information see "Adalimumab (including biosimilars): Drug information")

Dosage guidance:

Safety: Before therapy initiation, ensure appropriate immunization (if possible) and screen for active or latent infections. Treatment of tuberculosis (TB) infection (latent TB) is required before starting adalimumab. Avoid use in patients with severe active infections (Ref).

Dosage form information: In the United States, Abrilada (adalimumab-afzb), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm), Hadlima (adalimumab-bwwd), Hulio (adalimumab-fkjp), Hyrimoz (adalimumab-adaz), Idacio (adalimumab-aacf), Yuflyma (adalimumab-aaty), and Yusimry (adalimumab-aqvh) have been approved as biosimilars to Humira (adalimumab). In Canada, Abrilada, Amgevita, Hadlima, Hulio, Hyrimoz, Idacio, Simlandi, and Yuflyma are also approved as biosimilars to Humira; refer to Canadian product monograph(s) for biosimilar-specific indication details.

Axial spondyloarthritis, including ankylosing spondylitis

Axial spondyloarthritis, including ankylosing spondylitis (Humira and adalimumab biosimilars):

Note: Reserve for patients who do not have an adequate response to nonsteroidal anti-inflammatory drugs (NSAIDs); may continue NSAIDs and/or analgesics (Ref).

SUBQ: 40 mg every other week.

Crohn disease, moderate to severe, induction and maintenance of remission

Crohn disease, moderate to severe, induction and maintenance of remission (Humira and adalimumab biosimilars):

Note: Combination therapy with an immunomodulator (ie, thiopurine or methotrexate) is generally preferred (Ref).

Initial: SUBQ: 160 mg (given over 1 or 2 days), then 80 mg 2 weeks later (day 15). Note: If switching from another anti-tumor necrosis factor agent, may use this induction regimen.

Maintenance: SUBQ: 40 mg every other week beginning day 29.

Hidradenitis suppurativa, moderate to severe, refractory

Hidradenitis suppurativa, moderate to severe, refractory (Humira and adalimumab biosimilars):

Initial: SUBQ: 160 mg (given over 1 or 2 days), then 80 mg 2 weeks later (day 15).

Maintenance: SUBQ: 40 mg every week beginning day 29 or 80 mg every other week beginning day 29 (Ref). Note: 40 mg every week regimen has been more extensively studied and is therefore preferred by some experts (Ref).

Nonradiographic axial spondyloarthritis

Nonradiographic axial spondyloarthritis (off-label use):

Note: Reserve for patients who do not have an adequate response to NSAIDs; may continue NSAIDs and/or analgesics (Ref).

SUBQ: 40 mg every other week.

Peripheral spondyloarthritis, nonpsoriatic

Peripheral spondyloarthritis, nonpsoriatic (off-label use):

Note: May continue methotrexate, other nonbiologic DMARDs, corticosteroids, NSAIDs, and/or analgesics (Ref).

SUBQ: 40 mg every other week (Ref).

Plaque psoriasis, moderate to severe

Plaque psoriasis, moderate to severe (Humira and adalimumab biosimilars):

Note: Generally used as systemic monotherapy; may continue adjuvant topical therapies (eg, emollients, corticosteroids) as needed. A clinician experienced with use of adalimumab for plaque psoriasis should be involved in treatment.

Initial: SUBQ: 80 mg as a single dose.

Maintenance: SUBQ: 40 mg every other week beginning 1 week after initial dose. Note: Some patients may require 40 mg every week (Ref).

Psoriatic arthritis

Psoriatic arthritis (Humira and adalimumab biosimilars):

Note: May continue methotrexate, other nonbiologic DMARDs, corticosteroids, NSAIDs, and/or analgesics.

SUBQ: 40 mg every other week.

Rheumatoid arthritis

Rheumatoid arthritis (Humira and adalimumab biosimilars):

Note: For use as an alternative to methotrexate in disease-modifying antirheumatic drug (DMARD)–naive patients with moderate to high disease activity, or as adjunctive therapy in patients who have not met treatment goals despite maximally tolerated methotrexate therapy (Ref). May use in combination with other nonbiologic DMARDs, glucocorticoids, NSAIDs, and/or analgesics. A clinician experienced with use of adalimumab for rheumatoid arthritis should be involved in treatment.

SUBQ: Initial: 40 mg every other week; for select patients with an inadequate response, may increase dose to 40 mg every week or 80 mg every other week.

Sarcoidosis, refractory

Sarcoidosis, refractory (adjunctive agent) (off-label use):

Note: For use as an adjunctive agent in patients in whom treatment goals have not been met despite glucocorticoids and other immunosuppressants (eg, methotrexate) (Ref). A clinician experienced with use of adalimumab should be involved in treatment.

Initial: SUBQ: The optimal dosing strategy is not known; one example of an initial regimen is 40 to 120 mg on week 0, 40 to 80 mg on week 1, and 40 mg on week 2 (Ref).

Maintenance: SUBQ: 40 mg every 1 to 2 weeks (Ref). The optimal frequency and duration of therapy are not known and must be individualized based on response; after a stable response is achieved (eg, after 6 months), one option is to gradually prolong the dosing interval (eg, to every 2 weeks) and discontinue after 3 months if response remains adequate (Ref).

Ulcerative colitis, moderate to severe, induction and maintenance of remission

Ulcerative colitis, moderate to severe, induction and maintenance of remission (Humira and adalimumab biosimilars):

Initial: SUBQ: 160 mg (given over 1 or 2 days), then 80 mg 2 weeks later (day 15).

Maintenance: SUBQ: 40 mg every other week beginning day 29. If a disease flare occurs, some experts increase to 40 mg every week (Ref). Note: Only continue maintenance treatment in patients demonstrating clinical remission by 8 weeks (day 57) of therapy.

Uveitis, noninfectious

Uveitis, noninfectious (Humira and adalimumab biosimilars [except Yuflyma]):

Note: Generally reserved for patients with an incomplete response to first-line agents and ≥1 other systemic therapies (Ref).

Initial: SUBQ: 80 mg as a single dose.

Maintenance: SUBQ: 40 mg every other week beginning 1 week after initial dose.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Note: Theoretically, adalimumab’s large molecular weight (148,000 daltons) precludes the drug from being efficiently filtered at the glomerulus or by dialysis filters; hence, dose adjustments for kidney dysfunction and/or renal replacement therapies should generally be unnecessary (Ref).

Altered kidney function: SUBQ : No dosage adjustment necessary for any degree of kidney dysfunction (Ref).

Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m 2 ): Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Younger patients (<55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (Ref): SUBQ : No dosage adjustment necessary (Ref).

Hemodialysis, intermittent (thrice weekly): Unlikely to be significantly dialyzed (Ref): SUBQ : No dosage adjustment or supplemental dose necessary; patients with end-stage kidney disease (ESKD) often suffer from impaired immune function, monitor closely for infection during adalimumab therapy (Ref).

Peritoneal dialysis: Unlikely to be significantly dialyzed (Ref): SUBQ : No dosage adjustment necessary; patients with ESKD often suffer from impaired immune function; monitor closely for infection during adalimumab therapy (Ref).

CRRT: SUBQ : No dosage adjustment necessary (Ref).

PIRRT (eg, sustained, low-efficiency diafiltration): SUBQ : No dosage adjustment necessary (Ref).

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).

Adverse Reactions (Significant): Considerations
Autoimmune disorder

Antibody development may occur with the use of tumor necrosis factor alpha inhibitors (TNFai), including adalimumab. Most frequently, autoantibodies include anti-nuclear antibody (ANA) and anti-double stranded DNA (dsDNA); less frequently, anti-ENA, anti-histone Ab, and anti-cardiolipin Ab (Ref). Frequency of autoantibody development varies depending on underlying disease, specific TNFai medication, and the duration of use; the clinical significance of asymptomatic antibody positivity is unclear (Ref). Antibody positivity may rarely result in the development of an autoimmune disorder, such as lupus-like syndrome (Ref). Symptoms may include arthralgia, myalgia, mucocutaneous symptoms (eg, skin rash), cytopenia, fatigue, fever, serositis and kidney injury (Ref). Development of an autoimmune disorder is associated with a poor treatment response of the original disease to TNFai therapy (Ref). It is unclear if the development of an autoimmune disorder is a TNFai class effect; several reports of rechallenge with the same TNFai or a different TNFai after treatment of the initial autoimmune disorder did not result in a recurrence (Ref).

Mechanism: Unknown; Postulated mechanisms include bystander activation of autoreactive lymphocytes due to drug-specific immunity, nonspecific activation of lymphocytes, direct cytotoxicity with release of autoantigens, and disruption of central T-cell tolerance (Ref).

Onset: Varied; ranged from 5 weeks to 2 years (Ref).

Risk factors:

• Longer disease duration (Ref)

• Females (Ref)

• Ulcerative colitis (Ref)

Demyelinating disease

New-onset or exacerbation of central and peripheral nervous system demyelinating disease, such as multiple sclerosis, optic neuritis, acute transverse myelitis, Guillain-Barré syndrome, and chronic inflammatory demyelinating polyneuropathy may occur with tumor necrosis factor alpha inhibitors (TNFai), although causality has not been proven (Ref). Symptomatic CNS demyelination associated with TNFai may be monophasic and/or clinically isolated (Ref). Partial or complete resolution may occur after discontinuation of TNFai (Ref); however, approximately one-third of TNFai associated demyelinating episodes evolve into clinically definite multiple sclerosis (Ref).

Mechanism: Unknown; several mechanisms have been postulated, including the following: May trigger CNS demyelination directly by immune activation in genetically and/or immunologically predisposed individuals (Ref); may inhibit remyelination via TNF type-2 receptor (TNRF2) (Ref); may increase ingress of auto-reactive T cells in the CNS; may alter downstream cytokine responses; may neutralize TNF systemically but not within the CNS, creating an artificially high local concentration of brain TNF (known as sponge effect); may permit latent CNS viral infection; or may promote anti-drug antibodies and immune complexes that are contributory to demyelination events (Ref).

Onset: Varied; mean time of exposure to TNFai before onset of symptoms: 18 months (Ref).

Risk factors:

• Preexisting or recent onset central or peripheral nervous system demyelinating disease

Dermatologic reactions

Various cutaneous eruptions have been reported, including psoriasiform eruption (either new-onset or exacerbation), hidradenitis suppurativa, lupus-like syndrome, eczematous rash, pustular rash, lichenoid eruption, and hypersensitivity angiitis (Ref).

Mechanism: Psoriasiform eruptions, lichenoid drug eruptions: Non–dose-related; possibly related to cytokine imbalance or imbalance between tumor necrosis factor (TNF)-alpha and interferon-alpha (Ref).

Onset: Psoriasiform eruptions: Delayed: Mean 15.6 ± 10.7 months (Ref). Hidradenitis suppurativa: Delayed; median 12 months (range: 1 to 72) (Ref).

Risk factors:

• Adult females (psoriatic lesions) (Ref)

• Smoking (psoriatic lesions) (Ref)

• Males (palmoplantar pustulosis) (Ref)

• Younger patients (<40 years of age) (palmoplantar pustulosis) (Ref)

• Patients with inflammatory bowel disease compared to other inflammatory diseases (psoriasiform reactions more frequent and severe) (Ref).

• Females (hidradenitis suppurativa) (Ref)

• Cross-reactivity data among TNFai in patients who develop psoriatic lesions are conflicting (Ref)

Heart failure

New-onset heart failure (HF) and worsening of heart failure have been reported with tumor necrosis factor-alpha inhibitors (TNFai), including adalimumab; however, data are conflicting, and risk is unclear (Ref). Rheumatoid arthritis (RA) may be a risk factor for HF development (Ref). Some data suggest that TNFai may reduce the risk of HF in the RA population by improving inflammation, lowering disease activity, and improving surrogate markers of cardiovascular disease (Ref).

Mechanism: Not clearly established; postulated mechanisms include pro-inflammatory cytokine activation, accelerated atherosclerosis, and reduced physical activity related to the underlying rheumatologic disease (Ref). "Reverse-signaling" may occur, leading to cardiotoxic effects; TNF on cardiomyocytes of the failing heart may act as receptors, activating intracellular signaling pathways, potentiating the toxic effect of the cytokine (Ref).

Onset: Varied; median 8.5 months (range: 5 to 17 months (data with infliximab) (Ref).

Risk factors:

• Preexisting heart failure

• Higher disease activity (inflammation) (eg, disease activity score (DAS28), C-reactive protein, erythrocyte sedimentation rate) (Ref)

Hepatitis B virus reactivation

Reactivation of hepatitis B virus (HBV) may occur with immunosuppressive or biologic therapy, including tumor necrosis factor-alpha inhibitors (TNFai) (Ref). Reactivation of HBV may occur in both patients who are HBsAg-positive and in patients who are HBsAg-negative/HBcAb-positive with detectable HBV DNA (Ref). Criteria for HBV reactivation includes (1) a rise in HBV DNA compared to baseline (or an absolute level of HBV DNA when a baseline is unavailable) and (2) reverse seroconversion (seroreversion) from HBsAg negative to HBsAg positive for patients who are HBsAg-negative and anti-HBc–positive (Ref).

Mechanism: Inhibit stimulation of HBV specific T-lymphocytes, promoting reactivation (Ref).

Onset: Varied; 2 weeks after initiation, up to a year after discontinuation (Ref).

Risk factors:

• Males (Ref)

• Older age (Ref)

• Presence of cirrhosis (Ref)

• High baseline HBV-DNA level (Ref)

• HBeAg or HBsAg seropositivity (Ref)

• Absence of anti-HBs among patients with resolved HBV infection (Ref)

• Chronic HBV (Ref)

• Non-A HBV genotype (Ref)

• Hepatitis C, hepatitis D, or HIV co-infection (Ref)

Hepatoxicity

Adalimumab has been associated with increased serum transaminases and hepatotoxicity (Ref). Cholestatic hepatitis, reactivation of hepatitis B virus, and autoimmune hepatitis have been reported (Ref). Elevated aminotransferases between 2 to 3 times the upper limit of normal may occur that are usually transient and asymptomatic (Ref). Resolution of symptoms in patients who develop an autoimmune hepatitis may require initiation of corticosteroid therapy (Ref). Immunomodulatory use, in particular methotrexate, may decrease the risk of hepatotoxicity associated with tumor necrosis factor-alpha inhibitors (TNFai) (Ref). Patients often tolerate a different TNFai (Ref); although, hepatotoxicity may recur with an alternative agent in some cases (Ref). Hepatotoxicity is more commonly associated with infliximab, as compared to adalimumab and other TNFai (Ref).

Mechanism: Unknown; idiosyncratic drug reaction (Ref), or autoimmunity due to development of autoantibodies (Ref).

Onset: Varied; ranges from 4 weeks to 52 weeks (Ref). Autoimmune hepatitis has a longer latency period than non-immune cases (16 weeks vs 10 weeks, respectively) (Ref).

Infection

Tumor necrosis factor-alpha inhibitors (TNFai) may be associated with infection (including serious infection). In clinical trials, serious infections were numerically higher among patients treated with TNFai than among patients who received placebo. Meta-analyses and observational studies have reported inconsistency in risk. One study reported an increase in serious infection in patients treated with TNFai (Ref). Another study found no increase in risk (Ref). An observational study did not demonstrate an increased infection risk among patients receiving TNFai versus comparators (Ref). Infections may present as disseminated (rather than local) disease. Active tuberculosis (including reactivation of latent tuberculosis), invasive fungal infection (including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, and pneumocystosis) and bacterial infection, viral infection, or other opportunistic infections (including legionellosis and listeriosis) have been reported.

Mechanism: Dose-related; TNFa is important in the immune response against infections, suggesting that medications that inhibit TNFa may increase the risk of infections (Ref).

Risk factors:

• Higher doses (Ref)

• Older age (Ref)

• Chronic lung or kidney disease (Ref)

• Concurrent immunosuppressants (eg, corticosteroids, methotrexate) (Ref)

• History of an opportunistic infection

• Chronic or recurrent infection

• Conditions that predispose to infections (eg, advanced or poorly controlled diabetes)

• Residence/travel in areas of endemic tuberculosis or mycoses (blastomycosis, coccidioidomycosis, histoplasmosis)

Injection-site reactions

Adalimumab is associated with injection-site reactions and delayed reactions (Ref). Concurrent immunomodulators (eg, methotrexate, cyclosporine) reduce the development of anti-adalimumab antibodies and may reduce risk (Ref). Most reactions do not require discontinuation and do not recur (Ref). Cross-reactivity between tumor necrosis factor-alpha inhibitors is not well-described (Ref). Anti-infliximab antibodies do not crossreact with adalimumab; although, patients who develop anti-infliximab antibodies are more prone to develop anti-adalimumab antibodies (Ref). Adalimumab has been tolerated in patients with previous infusion reactions with infliximab (Ref). In contrast, there are reports of immediate hypersensitivity reactions with adalimumab in patients who had previous infliximab-related reactions (Ref).

Mechanism: Unknown; T-cell mediated (Ref) or IgE-mediated (Ref).

Onset: Varied; 12 to 24 hours following injection (but may occur immediately following injection). Injection-site reactions often occur within the first month of treatment and last up to 4 days (Ref).

Risk factors:

• Younger age (Ref)

Malignancy

Lymphoma and other malignancies (some fatal) have been reported in children and adolescents receiving tumor necrosis factor-alpha inhibitors (TNFai), including adalimumab. Half of the malignancies reported in children and adolescents were lymphomas (Hodgkin lymphoma and non-Hodgkin lymphoma), while other cases varied and included rare malignancies usually associated with immunosuppression and malignancies not typically observed in this population. Most patients were receiving concomitant immunosuppressants. Hepatosplenic T-cell lymphoma, a rare T-cell lymphoma, has been reported (some fatal), primarily in patients with Crohn disease or ulcerative colitis treated with adalimumab and who received concomitant azathioprine or mercaptopurine; reports occurred predominantly in adolescent and young adult males.

Long-term observational studies and meta-analyses indicate no association between TNFai therapy and an overall increased risk of cancer (Ref). One study reported a significant increase in lymphomas in patients with rheumatoid arthritis (RA) receiving TNFai compared to the general population. However, there was no significant increased risk of lymphomas in patients receiving TNFai compared to those receiving csDMARD or with dose, increasing time since initiation, or cumulative duration (Ref). Another study reported no difference in the risk of solid tumors in patients with RA receiving TNFai compared to those receiving csDMARDs (Ref). Other studies reported no increased risk of malignancy recurrence in patients receiving TNFai (Ref).

Mechanism: May contribute to protumor activity and suppress the anti-tumor response (Ref).

Onset: Delayed; median 30 months (range: 1 to 84 months).

Tuberculosis

Adult and pediatric patients treated with tumor necrosis factor-alpha inhibitors (TNFai) are at risk for developing active tuberculosis (TB) (including reactivated tuberculosis) (Ref). A meta-analysis of randomized controlled trials (RTC) of TNFai versus control and registry/longitudinal cohort studies of TNFai versus other DMARDs found a significant increase in TB risk in patients with rheumatoid arthritis (RA) treated with TNFai. In the non-RTC studies, incidence rates with adalimumab were higher than etanercept. Preventive treatment for latent TB infection reduced TB risk (Ref). In the RCT studies, no difference in TB rates were found; however, this failure to detect a difference in TB rates between the two groups may be due to a short observational period (Ref).

Mechanism: TNFai interfere with TNFa induction of the granuloma, which is a crucial defense mechanism in controlling TB (Ref). TNFai modulates T-cell number, function, and cytokine signaling, important for the control of TB infection (Ref).

Onset: Varied; median 3 to ~73 months (Ref).

Risk factors:

• Residence in an area with high TB prevalence (Ref)

• Known TB exposure or ongoing risk factors for TB exposure (eg, travel to areas with high TB prevalence, residence in correctional facilities, long-term care facilities, or homeless shelters, certain healthcare workers (Ref)

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

>10%:

Dermatologic: Skin rash (12%) (table 1)

Adalimumab: Adverse Reaction: Skin Rash

Drug (Adalimumab)

Placebo

Population

Dose

Indication

Number of Patients (Adalimumab)

Number of Patients (Placebo)

12%

6%

Adults

40 mg every other week

Rheumatoid Arthritis

705

690

Hematologic & oncologic: Positive ANA titer (12%)

Immunologic: Antibody development (3% to 26%)

Infection: Infection

Local: Injection-site reaction (5% to 20%; including bleeding at injection site, erythema at injection site, injection-site pruritus, pain at injection site, swelling at injection site) (table 2)

Adalimumab: Adverse Reaction: Injection-Site Reaction

Drug (Adalimumab)

Placebo

Population

Dose

Indication

Number of Patients (Adalimumab)

Number of Patients (Placebo)

16%

N/A

Children and adolescents

Either 24 mg/m2 up to maximum 40 mg every other week or 20 mg every other week (<30 kg), 40 mg every other week (≥30 kg) dependent on phase of study

Juvenile idiopathic arthritis

171

N/A

5%

N/A

Children and adolescents

High dose: 40 mg every other week (≥40 kg) or 20 mg every other week (<40 kg); low dose: 20 mg every other week (≥40 kg) or 10 mg every other week (<40 kg)

Crohn disease

192

N/A

8%

1%

Adults

40 mg every other week

Rheumatoid Arthritis

705

690

20%

14%

N/A

N/A

Pooled placebo-controlled clinical trials

N/A

N/A

Nervous system: Headache (12%)

Neuromuscular & skeletal: Increased creatine phosphokinase in blood specimen (children and adolescents: 15%)

Respiratory: Sinusitis (11%), upper respiratory tract infection (17%)

1% to 10%:

Cardiovascular: Acute myocardial infarction (<5%), atrial fibrillation (<5%), cardiac arrhythmia (<5%), chest pain (<5%), coronary artery disease (<5%), deep vein thrombosis (<5%), hypertension (5%), hypertensive encephalopathy (<5%), palpitations (<5%), pericardial effusion (<5%), pericarditis (<5%), peripheral edema (<5%), syncope (<5%), tachycardia (<5%)

Endocrine & metabolic: Dehydration (<5%), hypercholesterolemia (6%), hyperlipidemia (7%), ketosis (<5%), menstrual disease (<5%), parathyroid disease (<5%)

Gastrointestinal: Abdominal pain (7%), cholecystitis (<5%), cholelithiasis (<5%), esophagitis (<5%), gastroenteritis (<5%), gastrointestinal hemorrhage (<5%), nausea (9%), vomiting (<5%)

Genitourinary: Cystitis (<5%), hematuria (5%), pelvic pain (<5%), urinary tract infection (8%)

Hematologic & oncologic: Adenoma (<5%), agranulocytosis (<5%), paraproteinemia (<5%), polycythemia (<5%)

Hepatic: Hepatic necrosis (<5%), increased serum alkaline phosphatase (5%)

Hypersensitivity: Hypersensitivity reaction (children and adolescents: 5% to 6%)

Infection: Herpes simplex infection (≤4%), herpes zoster infection (≤4%), serious infection (4% to 5%)

Nervous system: Confusion (<5%), myasthenia (<5%), paresthesia (<5%), subdural hematoma (<5%), torso pain (<5%), tremor (<5%)

Neuromuscular & skeletal: Arthralgia (3%), arthritis (<5%, including pyogenic arthritis), arthropathy (<5%), back pain (6%), bone disease (<5%), bone fracture (<5%), limb pain (<5%), muscle cramps (<5%), osteonecrosis (<5%), synovitis (<5%), tendinopathy (<5%)

Ophthalmic: Cataract (<5%)

Renal: Nephrolithiasis (<5%)

Respiratory: Asthma (<5%), bronchospasm (<5%), dyspnea (<5%), flu-like symptoms (7%), pharyngitis (≤4%), pleural effusion (<5%), pneumonia (≤4%), respiratory depression (<5%)

Miscellaneous: Abnormal healing (<5%), accidental injury (10%)

<1%: Neuromuscular & skeletal: Lupus-like syndrome (Schiff 2006)

Frequency not defined:

Dermatologic: Basal cell carcinoma of skin, cellulitis, erysipelas, malignant melanoma, skin granuloma (annulare; children and adolescents)

Gastrointestinal: Appendicitis

Genitourinary: Uterine hemorrhage

Hematologic & oncologic: Carcinoma (including breast, gastrointestinal, lung, skin, urogenital), malignant lymphoma, neutropenia (children and adolescents)

Hepatic: Increased serum transaminases

Infection: Atypical mycobacterial infection, bacterial infection, fungal infection (including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, and infection due to an organism in genus Pneumocystis), influenza (H1N1), opportunistic infection (including Legionella and listeriosis), parasitic infection, postoperative infection, sepsis (including catheter related sepsis), viral infection

Neuromuscular & skeletal: Myositis (children and adolescents), septic arthritis

Renal: Pyelonephritis

Respiratory: Bronchitis, nasopharyngitis, streptococcal pharyngitis (children and adolescents), tuberculosis (including reactivated tuberculosis; disseminated, miliary, lymphatic, peritoneal, and pulmonary)

Postmarketing:

Cardiovascular: Heart failure (Mansitó López 2021), pulmonary embolism, vasculitis (systemic), worsening of heart failure

Dermatologic: Alopecia, cutaneous lupus erythematosus (Gonzalez-Cuevas 2020), eczematous rash (Moustou 2009), erythema multiforme, fixed drug eruption, lichenoid eruption (Moustou 2009), Merkel cell carcinoma, psoriasiform eruption (Bae 2018a), psoriasis (including new onset, palmoplantar, pustular, or exacerbation), pustular rash (Moustou 2009), Stevens-Johnson syndrome (Mounach 2013), urticaria (Grace 2020)

Gastrointestinal: Diverticulitis of the gastrointestinal tract, gastrointestinal perforation (appendiceal perforations), intestinal perforation, pancreatitis

Hematologic & oncologic: Aplastic anemia, hepatosplenic T-cell lymphomas (children, adolescents, and young adults), leukopenia, pancytopenia, thrombocytopenia

Hepatic: Autoimmune hepatitis (Adar 2010), cholestatic hepatitis (Latus 2013), hepatic failure, hepatitis, hepatotoxicity (idiosyncratic) (Chalasani 2021)

Hypersensitivity: Anaphylaxis (Steenholdt 2012), angioedema (Hansel 2019), hypersensitivity angiitis (Amarantee 2015), nonimmune anaphylaxis

Immunologic: Sarcoidosis

Infection: Reactivation of HBV (Loomba 2017)

Nervous system: Cerebrovascular accident, demyelinating disease (peripheral; including Guillain-Barré syndrome) (Kemanetzoglou 2017), demyelinating disease of the central nervous system (including multiple sclerosis) (Kemanetzoglou 2017)

Ophthalmic: Optic neuritis

Respiratory: Interstitial lung disease (including pulmonary fibrosis)

Miscellaneous: Fever (Choi 2021)

Contraindications

There are no contraindications listed in the manufacturer's US labeling.

Canadian labeling: Known hypersensitivity to adalimumab or any component of the formulation; severe infection (eg, sepsis, tuberculosis, opportunistic infection); moderate-to-severe heart failure (NYHA class III/IV)

Warnings/Precautions

Concerns related to adverse effects:

• Antibody formation: Formation of neutralizing anti-drug antibodies may occur with biologic tumor necrosis factor (TNF) inhibitors and may be associated with loss of efficacy (AAD-NPF [Menter 2019]).

• Hematologic disorders: Rare cases of pancytopenia and aplastic anemia have been reported with TNF-blockers. Patients must be advised to seek medical attention if they develop signs and symptoms suggestive of blood dyscrasias; discontinue if significant hematologic abnormalities are confirmed. Use with caution in patients with a history of significant hematologic abnormalities.

Disease-related concerns:

• Active infection: Do not initiate therapy in patients with an active infection, including clinically important localized infection.

• HIV: Use with caution in HIV-positive patients; TNF-α inhibitors may be appropriate in patients receiving highly active antiretroviral therapy, provided they have normal CD4 counts, no viral load, and no recent opportunistic infections (AAD-NPF [Menter 2019]).

Special populations:

• Patients with rheumatic musculoskeletal disease undergoing hip or knee replacement surgery: Hold biologic disease-modifying antirheumatic drugs (DMARDs) prior to surgery and plan surgery after the next dose is due. Surgery can occur after holding medication for 1 full dosing cycle (eg, for medications administered every 4 weeks, schedule surgery 5 weeks from last administered dose); therapy can be restarted once surgical wound shows evidence of healing (eg, no swelling, erythema, or drainage), sutures/staples are removed, and no ongoing nonsurgical site infections (typically ~14 days to reduce infection risk). Decisions to withhold therapy should be based on shared decision making; ensure the patient and their provider weigh risks of interrupting therapy and disease control versus risks of continuing therapy and surgical complications (ACR/AAHKS [Goodman 2022]).

• Surgery patients: Limited experience with patients undergoing surgical procedures while on therapy; consider long half-life with planned procedures. Monitor closely for infection.

Dosage form specific issues:

• Latex: The packaging (needle cover of prefilled syringe and autoinjector) may contain latex.

• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.

Other warnings/precautions:

• Immunizations: Patients should be brought up to date with all immunizations before initiating therapy; live vaccines should not be given concurrently. There are no data available concerning the effects of therapy on vaccination or secondary transmission of live vaccines in patients receiving therapy.

Dosage Forms Considerations

Humira 10 mg/0.1 mL, 20 mg/0.2 mL, 40 mg/0.4 mL, and 80 mg/0.8 mL formulations are citrate free. All Humira biosimilars are citrate free except for Hadlima 40 mg/0.8 mL.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Auto-injector Kit, Subcutaneous:

Hulio: Adalimumab-fkjp 40 mg/0.8 mL (1 ea) [contains polysorbate 80]

Generic: Adalimumab-adbm 40 mg/0.8 mL (1 ea)

Auto-injector Kit, Subcutaneous [preservative free]:

Abrilada: Adalimumab-afzb 40 mg/0.8 mL (1 ea) [contains edetate (edta) disodium dihydrate, polysorbate 80]

Cyltezo: Adalimumab-adbm 40 mg/0.8 mL (1 ea) [contains polysorbate 80]

Cyltezo-CD/UC/HS Starter: Adalimumab-adbm 40 mg/0.8 mL (1 ea) [contains polysorbate 80]

Cyltezo-Psoriasis Starter: Adalimumab-adbm 40 mg/0.8 mL (1 ea) [contains polysorbate 80]

Idacio: Adalimumab-aacf 40 mg/0.8 mL (1 ea) [contains polysorbate 80]

Idacio for Crohns Disease/UC: Adalimumab-aacf 40 mg/0.8 mL (1 ea) [contains polysorbate 80]

Idacio for Plaque Psoriasis: Adalimumab-aacf 40 mg/0.8 mL (1 ea) [contains polysorbate 80]

Yuflyma: Adalimumab-aaty 80 mg/0.8 mL (1 ea) [contains polysorbate 80]

Yuflyma 1-Pen Kit: Adalimumab-aaty 40 mg/0.4 mL (1 ea) [contains polysorbate 80]

Yuflyma 2-Pen Kit: Adalimumab-aaty 40 mg/0.4 mL (1 ea) [contains polysorbate 80]

Yuflyma-CD/UC/HS Starter: Adalimumab-aaty 80 mg/0.8 mL (1 ea) [contains polysorbate 80]

Generic: Adalimumab-aacf 40 mg/0.8 mL (1 ea); Adalimumab-fkjp 40 mg/0.8 mL (1 ea)

Pen-injector Kit, Subcutaneous [preservative free]:

Humira Pen: 40 mg/0.8 mL (1 ea); 40 mg/0.4 mL (1 ea); 80 mg/0.8 mL (1 ea) [contains polysorbate 80]

Humira Pen-CD/UC/HS Starter: 40 mg/0.8 mL (1 ea); 80 mg/0.8 mL (1 ea) [contains polysorbate 80]

Humira Pen-Pediatric UC Start: 80 mg/0.8 mL (1 ea) [latex free; contains polysorbate 80]

Humira Pen-Ps/UV/Adol HS Start: 40 mg/0.8 mL (1 ea) [contains polysorbate 80]

Humira Pen-Psor/Uveit Starter: 80 MG/0.8ML & 40MG/0.4ML (1 ea) [contains polysorbate 80]

Prefilled Syringe Kit, Subcutaneous:

Hulio: Adalimumab-fkjp 40 mg/0.8 mL (1 ea) [contains polysorbate 80]

Yuflyma 2-Syringe Kit: Adalimumab-aaty 40 mg/0.4 mL (1 ea) [contains polysorbate 80]

Generic: 20 mg/0.4 mL (1 ea); 40 mg/0.8 mL (1 ea); Adalimumab-adbm 10 MG/0.2 mL (1 ea)

Prefilled Syringe Kit, Subcutaneous [preservative free]:

Abrilada: Adalimumab-afzb 20 mg/0.4 mL (1 ea); Adalimumab-afzb 40 mg/0.8 mL (1 ea) [contains edetate (edta) disodium dihydrate, polysorbate 80]

Cyltezo: 20 mg/0.4 mL (1 ea); 40 mg/0.8 mL (1 ea); Adalimumab-adbm 10 MG/0.2 mL (1 ea) [contains polysorbate 80]

Hulio: Adalimumab-fkjp 20 mg/0.4 mL (1 ea) [contains polysorbate 80]

Humira: 10 mg/0.2 mL (1 ea [DSC]); 20 mg/0.4 mL (1 ea [DSC]); 40 mg/0.8 mL (1 ea); 10 mg/0.1 mL (1 ea); 20 mg/0.2 mL (1 ea); 40 mg/0.4 mL (1 ea) [contains polysorbate 80]

Humira Pediatric Crohns Start: 80 mg/0.8 mL (1 ea); 80 MG/0.8ML & 40MG/0.4ML (1 ea) [contains polysorbate 80]

Idacio: Adalimumab-aacf 40 mg/0.8 mL (1 ea) [contains polysorbate 80]

Generic: Adalimumab-fkjp 20 mg/0.4 mL (1 ea); Adalimumab-fkjp 40 mg/0.8 mL (1 ea)

Solution, Subcutaneous:

Generic: 20,000 pn unit/mL (10 mL [DSC], 50 mL [DSC])

Solution Auto-injector, Subcutaneous [preservative free]:

Amjevita: Adalimumab-atto 40 mg/0.4 mL (0.4 mL); Adalimumab-atto 80 mg/0.8 mL (0.8 mL); Adalimumab-atto 40 mg/0.8 mL (0.8 mL) [latex free; contains polysorbate 80]

Hadlima PushTouch: Adalimumab-bwwd 40 mg/0.4 mL (0.4 mL); Adalimumab-bwwd 40 mg/0.8 mL (0.8 mL)

Hyrimoz: Adalimumab-adaz 40 mg/0.4 mL (0.4 mL); Adalimumab-adaz 40 mg/0.8 mL (0.8 mL) [latex free; contains polysorbate 80]

Hyrimoz: Adalimumab-adaz 40 mg/0.4 mL (0.4 mL); Adalimumab-adaz 80 mg/0.8 mL (0.8 mL) [contains polysorbate 80]

Hyrimoz-Crohns/UC Starter: Adalimumab-adaz 80 mg/0.8 mL (0.8 mL) [contains polysorbate 80]

Hyrimoz-Plaque Psoriasis Start: Adalimumab-adaz 80 mg/0.8 mL and 40 mg/0.4 mL (1.6 mL) [contains polysorbate 80]

Generic: Adalimumab-adaz 40 mg/0.4 mL (0.4 mL)

Solution Pen-injector, Subcutaneous [preservative free]:

Yusimry: Adalimumab-aqvh 40 mg/0.8 mL (0.8 mL) [contains polysorbate 80]

Solution Prefilled Syringe, Subcutaneous:

Amjevita: Adalimumab-atto 20 mg/0.4 mL (0.4 mL); Adalimumab-atto 40 mg/0.8 mL (0.8 mL) [latex free; contains polysorbate 80]

Solution Prefilled Syringe, Subcutaneous [preservative free]:

Amjevita: Adalimumab-atto 20 mg/0.2 mL (0.2 mL); Adalimumab-atto 40 mg/0.4 mL (0.4 mL) [latex free; contains polysorbate 80]

Amjevita: Adalimumab-atto 10 mg/0.2 mL (0.2 mL) [contains polysorbate 80]

Hadlima: Adalimumab-bwwd 40 mg/0.4 mL (0.4 mL); Adalimumab-bwwd 40 mg/0.8 mL (0.8 mL)

Hyrimoz: Adalimumab-adaz 40 mg/0.4 mL (0.4 mL); Adalimumab-adaz 40 mg/0.8 mL (0.8 mL) [latex free; contains polysorbate 80]

Hyrimoz: Adalimumab-adaz 10 mg/0.1 mL (0.1 mL); Adalimumab-adaz 20 mg/0.2 mL (0.2 mL); Adalimumab-adaz 40 mg/0.4 mL (0.4 mL) [contains polysorbate 80]

Hyrimoz-Ped>/=40kg Crohn Start: Adalimumab-adaz 80 mg/0.8 mL (0.8 mL) [contains polysorbate 80]

Hyrimoz-Ped<40kg Crohn Starter: Adalimumab-adaz 80 mg/0.8 mL (1.2 mL) [contains polysorbate 80]

Generic: Adalimumab-adaz 40 mg/0.4 mL (0.4 mL)

Generic Equivalent Available: US

May be product dependent

Pricing: US

Auto-injector Kit (Abrilada Subcutaneous)

40 mg/0.8 mL (per each): $3,945.90

Auto-injector Kit (Adalimumab-aacf Subcutaneous)

40 mg/0.8 mL (per each): $1,078.80

Auto-injector Kit (Adalimumab-adbm Subcutaneous)

40 mg/0.8 mL (per each): $789.18

Auto-injector Kit (Adalimumab-fkjp Subcutaneous)

40 mg/0.8 mL (per each): $597.00

Auto-injector Kit (Cyltezo Subcutaneous)

40 mg/0.8 mL (per each): $3,945.90

Auto-injector Kit (Cyltezo-CD/UC/HS Starter Subcutaneous)

40 mg/0.8 mL (per each): $3,945.89

Auto-injector Kit (Cyltezo-Psoriasis Starter Subcutaneous)

40 mg/0.8 mL (per each): $3,945.90

Auto-injector Kit (Hulio Subcutaneous)

40 mg/0.8 mL (per each): $3,945.90

Auto-injector Kit (Idacio for Crohns Disease/UC Subcutaneous)

40 mg/0.8 mL (per each): $7,891.79

Auto-injector Kit (Idacio for Plaque Psoriasis Subcutaneous)

40 mg/0.8 mL (per each): $7,891.79

Auto-injector Kit (Idacio Subcutaneous)

40 mg/0.8 mL (per each): $7,891.79

Auto-injector Kit (Yuflyma 1-Pen Kit Subcutaneous)

40 mg/0.4 mL (per each): $3,945.90

Auto-injector Kit (Yuflyma 2-Pen Kit Subcutaneous)

40 mg/0.4 mL (per each): $7,891.80

Auto-injector Kit (Yuflyma Subcutaneous)

80 mg/0.8 mL (per each): $3,945.90

Auto-injector Kit (Yuflyma-CD/UC/HS Starter Subcutaneous)

80 mg/0.8 mL (per each): $3,945.90

Pen-injector Kit (Humira Pen Subcutaneous)

40 mg/0.4 mL (per each): $4,153.57

40 mg/0.8 mL (per each): $4,153.57

80 mg/0.8 mL (per each): $8,307.16

Pen-injector Kit (Humira Pen-CD/UC/HS Starter Subcutaneous)

40 mg/0.8 mL (per each): $4,153.59

80 mg/0.8 mL (per each): $8,307.18

Pen-injector Kit (Humira Pen-Pediatric UC Start Subcutaneous)

80 mg/0.8 mL (per each): $8,307.16

Pen-injector Kit (Humira Pen-Ps/UV/Adol HS Start Subcutaneous)

40 mg/0.8 mL (per each): $4,153.58

Pen-injector Kit (Humira Pen-Psor/Uveit Starter Subcutaneous)

80 MG/0.8ML &40MG/0.4ML (per each): $5,538.11

Prefilled Syringe Kit (Abrilada Subcutaneous)

20 mg/0.4 mL (per each): $3,945.90

40 mg/0.8 mL (per each): $3,945.90

Prefilled Syringe Kit (Adalimumab-adbm Subcutaneous)

10 mg/0.2 mL (per each): $789.18

20 mg/0.4 mL (per each): $789.18

40 mg/0.8 mL (per each): $789.18

Prefilled Syringe Kit (Adalimumab-fkjp Subcutaneous)

20 mg/0.4 mL (per each): $597.00

40 mg/0.8 mL (per each): $597.00

Prefilled Syringe Kit (Cyltezo Subcutaneous)

10 mg/0.2 mL (per each): $3,945.90

20 mg/0.4 mL (per each): $3,945.90

40 mg/0.8 mL (per each): $3,945.90

Prefilled Syringe Kit (Hulio Subcutaneous)

20 mg/0.4 mL (per each): $3,945.90

40 mg/0.8 mL (per each): $3,945.90

Prefilled Syringe Kit (Humira Pediatric Crohns Start Subcutaneous)

80 mg/0.8 mL (per each): $8,307.18

80 MG/0.8ML &40MG/0.4ML (per each): $6,230.38

Prefilled Syringe Kit (Humira Subcutaneous)

10MG/0.1ML (per each): $4,153.57

20 mg/0.2 mL (per each): $4,153.57

40 mg/0.4 mL (per each): $4,153.57

40 mg/0.8 mL (per each): $4,153.57

Prefilled Syringe Kit (Idacio Subcutaneous)

40 mg/0.8 mL (per each): $7,891.79

Prefilled Syringe Kit (Yuflyma 2-Syringe Kit Subcutaneous)

40 mg/0.4 mL (per each): $7,891.80

Solution Auto-injector (Adalimumab-adaz Subcutaneous)

40 mg/0.4 mL (per 0.4 mL): $789.18

Solution Auto-injector (Amjevita Subcutaneous)

40 mg/0.8 mL (per 0.8 mL): $1,869.11

Solution Auto-injector (Hadlima PushTouch Subcutaneous)

40 mg/0.4 mL (per 0.4 mL): $622.80

40 mg/0.8 mL (per 0.8 mL): $622.80

Solution Auto-injector (Hyrimoz Subcutaneous)

40 mg/0.4 mL (per 0.4 mL): $780.00

40 mg/0.8 mL (per 0.8 mL): $780.00

80 mg/0.8 mL (per 0.8 mL): $7,891.81

Solution Auto-injector (Hyrimoz-Crohns/UC Starter Pack Subcutaneous)

80 mg/0.8 mL (per 0.8 mL): $7,891.82

Solution Auto-injector (Hyrimoz-Plaque Psoriasis Start Subcutaneous)

80 MG/0.8ML &40MG/0.4ML (per mL): $9,864.76

Solution Pen-injector (Yusimry Subcutaneous)

40 mg/0.8 mL (per 0.8 mL): $597.00

Solution Prefilled Syringe (Adalimumab-adaz Subcutaneous)

40 mg/0.4 mL (per 0.4 mL): $789.18

Solution Prefilled Syringe (Amjevita Subcutaneous)

10 mg/0.2 mL (per 0.2 mL): $3,945.89

20 mg/0.4 mL (per 0.4 mL): $3,945.89

40 mg/0.8 mL (per 0.8 mL): $3,945.89

Solution Prefilled Syringe (Hadlima Subcutaneous)

40 mg/0.4 mL (per 0.4 mL): $622.80

40 mg/0.8 mL (per 0.8 mL): $622.80

Solution Prefilled Syringe (Hyrimoz Subcutaneous)

10MG/0.1 ML (per 0.1 mL): $3,945.90

20 mg/0.2 mL (per 0.2 mL): $3,945.90

40 mg/0.4 mL (per 0.4 mL): $780.00

40 mg/0.8 mL (per 0.8 mL): $780.00

Solution Prefilled Syringe (Hyrimoz-Ped Crohns Starter Subcutaneous)

80 mg/0.8 mL (per 0.8 mL): $7,891.82

80 MG/0.8ML &40MG/0.4ML (per mL): $9,864.76

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Auto-injector Kit, Subcutaneous:

Simlandi: 40 mg/0.4 mL (1 ea, 2 ea) [contains polysorbate 80]

Yuflyma: Adalimumab-aaty 40 mg/0.4 mL (1 ea, 2 ea, 4 ea, 6 ea); Adalimumab-aaty 80 mg/0.8 mL (1 ea) [contains polysorbate 80]

Pen-injector Kit, Subcutaneous:

Hulio: 40 mg/0.8 mL (2 ea) [contains polysorbate 80]

Prefilled Syringe Kit, Subcutaneous:

Hulio: 20 mg/0.4 mL (2 ea); 40 mg/0.8 mL (2 ea) [contains polysorbate 80]

Simlandi: 40 mg/0.4 mL (1 ea, 2 ea); 80 mg/0.8 mL (1 ea, 2 ea) [contains polysorbate 80]

Yuflyma: Adalimumab-aaty 40 mg/0.4 mL (1 ea); Adalimumab-aaty 80 mg/0.8 mL (1 ea) [contains polysorbate 80]

Solution, Subcutaneous:

Humira: 40 mg/0.8 mL (0.8 mL) [contains polysorbate 80]

Solution Auto-injector, Subcutaneous:

Abrilada: 40 mg/0.8 mL (0.8 mL) [contains edetate (edta) disodium dihydrate, polysorbate 80]

Amgevita SureClick: 40 mg/0.8 mL (0.8 mL) [contains polysorbate 80]

Hadlima PushTouch: 40 mg/0.8 mL (0.8 mL)

Hyrimoz: 40 mg/0.8 mL (0.8 mL) [contains polysorbate 80]

Idacio: 40 mg/0.8 mL (0.8 mL) [contains polysorbate 80]

Solution Pen-injector, Subcutaneous:

Humira: 40 mg/0.4 mL ([DSC]) [contains polysorbate 80]

Solution Prefilled Syringe, Subcutaneous:

Abrilada: 20 mg/0.4 mL (0.4 mL); 40 mg/0.8 mL (0.8 mL) [contains edetate (edta) disodium dihydrate, polysorbate 80]

Amgevita: 20 mg/0.4 mL (0.4 mL); 40 mg/0.8 mL (0.8 mL) [contains polysorbate 80]

Hadlima: 40 mg/0.8 mL (0.8 mL)

Humira: 20 mg/0.2 mL (0.2 mL); 40 mg/0.4 mL ([DSC]) [contains polysorbate 80]

Hyrimoz: 20 mg/0.4 mL (0.4 mL); 40 mg/0.8 mL (0.8 mL) [contains polysorbate 80]

Idacio: 40 mg/0.8 mL (0.8 mL) [contains polysorbate 80]

Administration: Pediatric

SubQ: Administer subcutaneously into thigh or lower abdomen (avoid areas within 2 inches of navel); rotate injection sites. If single dose requires multiple injections, administer each injection at a separate site at least 1 inch apart. Do not administer into skin that is red, tender, bruised, or hard. May leave at room temperature for ~15 to 30 minutes prior to use; do not remove cap or cover while allowing product to reach room temperature. Do not use if solution is discolored or contains particulate matter.

Single-use vial: Intended for institutional use only; does not contain a preservative; discard unused portion.

Prefilled pens/syringe: Citrate-free formulations are available and may be associated with less pain on injection. Needle cap of the prefilled syringe or needle cover may contain latex. Pinch area of skin prepped for injection and continue to hold until injection complete. Hold pen firmly against pinched skin and press button. A loud click is heard when injection has begun. Continue to hold pen against skin until injection complete (may take 10 seconds). When injection is complete, the yellow indicator will fully appear in the window view and stop moving. See product labeling for administration details.

Administration: Adult

SUBQ: For SUBQ injection at separate sites in the thigh or lower abdomen (avoiding areas within 2 inches of navel); rotate injection sites. May leave at room temperature for ~15 to 30 minutes prior to use; do not remove cap or cover while allowing product to reach room temperature. Do not use if solution is discolored or contains particulate matter. Do not administer to skin which is red, tender, bruised, hard, or that has scars, stretch marks, or psoriasis plaques. Needle cap of the prefilled syringe or needle cover for the adalimumab pen may contain latex. Prefilled pens and syringes are available for use by patients and the full amount of the syringe should be injected (self-administration); the vial is intended for institutional use only. Vials do not contain a preservative; discard unused portion. Citrate-free formulations may be associated with less pain on injection.

Storage/Stability

Store at 2°C to 8°C (36°F to 46°F) in original container to protect from light; do not freeze. Do not use if frozen even if it has been thawed. Do not store in extreme heat or cold. If needed, may be stored at room temperature; allowable temperature range and duration of storage vary by product; refer to manufacturer’s labeling for detailed recommendations.

Use

Treatment of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) alone or in combination with methotrexate (Humira: FDA approved in ages 2 to 17 years weighing ≥10 kg); treatment and maintenance of remission in patients with moderately to severely active ulcerative colitis (Humira: FDA approved in ages ≥5 years and adults); treatment and maintenance of remission in patients with moderately to severely active Crohn disease (Humira: FDA approved in ages ≥6 years and adults); treatment of noninfectious intermediate, posterior, and panuveitis (Humira: FDA approved in ages ≥2 years weighing ≥10 kg and adults); treatment of moderate to severe hidradenitis suppurativa (Humira: FDA approved in ages ≥12 years weighing ≥30 kg and adults); treatment of moderately to severely active rheumatoid arthritis (RA) alone or in combination with methotrexate or other nonbiologic, disease-modifying antirheumatic drugs (DMARDs) (Humira: FDA approved in adults); treatment of active psoriatic arthritis alone or in combination with nonbiologic DMARDs (Humira: FDA approved in adults); treatment of active ankylosing spondylitis (Humira: FDA approved in adults); treatment of moderate to severe chronic plaque psoriasis when systemic therapy is required and other agents are less appropriate (Humira: FDA approved in adults).

Note: In the United States, Amjevita (adalimumab-atto) has been approved as a biosimilar to Humira (adalimumab). In Canada, Abrilada, Amgevita, Hadlima, Hulio, Hyrimoz, Idacio, Simlandi, and Yuflyma are also approved as biosimilars to Humira; refer to Canadian product monograph(s) for biosimilar-specific indication details. Approved ages and uses may vary (consult product labeling).

Medication Safety Issues
Sound-alike/look-alike issues:

Adalimumab may be confused with sarilumab.

Humira may be confused with Humulin, Humalog

Humira Pen may be confused with HumaPen Memoir (used with HumaLOG)

Yuflyma may be confused with Yusimry

High alert medication:

The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Abatacept: Anti-TNF Agents may enhance the immunosuppressive effect of Abatacept. Risk X: Avoid combination

Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents). Risk X: Avoid combination

Anakinra: Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported. Risk X: Avoid combination

Anifrolumab: Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) may enhance the immunosuppressive effect of Anifrolumab. Risk X: Avoid combination

Antithymocyte Globulin (Equine): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. Risk C: Monitor therapy

Baricitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Baricitinib. Risk X: Avoid combination

BCG Products: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of BCG Products. Risk X: Avoid combination

Belimumab: May enhance the immunosuppressive effect of Biologic Disease-Modifying Antirheumatic Drugs (DMARDs). Management: Consider alternatives to the use of belimumab with other biologic therapies. Monitor closely for increased toxicities related to additive immunosuppression (ie, infection, malignancy) if combined. Risk D: Consider therapy modification

Biologic Disease-Modifying Antirheumatic Drugs (DMARDs): May enhance the immunosuppressive effect of other Biologic Disease-Modifying Antirheumatic Drugs (DMARDs). Risk X: Avoid combination

Brincidofovir: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Brincidofovir. Risk C: Monitor therapy

Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Therapeutic Immunosuppressant Agents). Risk X: Avoid combination

Canakinumab: Anti-TNF Agents may enhance the adverse/toxic effect of Canakinumab. Specifically, the risk for serious infections and/or neutropenia may be increased. Risk X: Avoid combination

Certolizumab Pegol: Anti-TNF Agents may enhance the immunosuppressive effect of Certolizumab Pegol. Risk X: Avoid combination

Chikungunya Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). Risk X: Avoid combination

Cladribine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Cladribine. Risk X: Avoid combination

Coccidioides immitis Skin Test: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test. Management: Consider discontinuing therapeutic immunosuppressants several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results. Risk D: Consider therapy modification

COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector). Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters). Risk D: Consider therapy modification

COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). Risk C: Monitor therapy

COVID-19 Vaccine (mRNA): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA). Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details. Risk D: Consider therapy modification

COVID-19 Vaccine (Subunit): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). Risk C: Monitor therapy

COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). Risk C: Monitor therapy

CycloSPORINE (Systemic): Adalimumab may decrease the serum concentration of CycloSPORINE (Systemic). Risk C: Monitor therapy

CYP Substrates (Narrow Therapeutic Index/Sensitive with Inducers): Adalimumab may decrease the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inducers). Risk C: Monitor therapy

Dengue Tetravalent Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). Risk X: Avoid combination

Denosumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Denosumab. Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor for signs/symptoms of serious infections. Risk D: Consider therapy modification

Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents). Risk X: Avoid combination

Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents. Risk C: Monitor therapy

Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents). Risk X: Avoid combination

Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents). Risk X: Avoid combination

Inebilizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Inebilizumab. Risk C: Monitor therapy

Influenza Virus Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Influenza Virus Vaccines. Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate 2 to 3 months after therapy discontinued if immune competence restored. Risk D: Consider therapy modification

Leflunomide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Leflunomide. Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents. Risk D: Consider therapy modification

Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Risk X: Avoid combination

Nadofaragene Firadenovec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. Risk X: Avoid combination

Natalizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Natalizumab. Risk X: Avoid combination

Ocrelizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ocrelizumab. Risk C: Monitor therapy

Ofatumumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ofatumumab. Risk C: Monitor therapy

Pidotimod: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pidotimod. Risk C: Monitor therapy

Pimecrolimus: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Pimecrolimus. Risk X: Avoid combination

Pneumococcal Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pneumococcal Vaccines. Risk C: Monitor therapy

Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Risk X: Avoid combination

Polymethylmethacrylate: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate. Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration. Risk D: Consider therapy modification

Rabies Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Rabies Vaccine. Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine. Risk D: Consider therapy modification

Rilonacept: Anti-TNF Agents may enhance the adverse/toxic effect of Rilonacept. Risk X: Avoid combination

Ritlecitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ritlecitinib. Risk X: Avoid combination

Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents. Risk C: Monitor therapy

Ruxolitinib (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). Risk X: Avoid combination

Sipuleucel-T: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Sipuleucel-T. Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy. Risk D: Consider therapy modification

Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents). Risk C: Monitor therapy

Tacrolimus (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). Risk X: Avoid combination

Talimogene Laherparepvec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. Risk X: Avoid combination

Tertomotide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Tertomotide. Risk X: Avoid combination

Theophylline Derivatives: Adalimumab may decrease the serum concentration of Theophylline Derivatives. Risk C: Monitor therapy

Thiopurine Analogs: Anti-TNF Agents may enhance the adverse/toxic effect of Thiopurine Analogs. Specifically, the risk for T-cell non-Hodgkin's lymphoma (including hepatosplenic T-cell lymphoma) may be increased. Risk C: Monitor therapy

Tofacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tofacitinib. Management: Coadministration of tofacitinib with potent immunosuppressants is not recommended. Use with non-biologic disease-modifying antirheumatic drugs (DMARDs) was permitted in psoriatic arthritis clinical trials. Risk X: Avoid combination

Typhoid Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Typhoid Vaccine. Risk X: Avoid combination

Ublituximab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ublituximab. Risk C: Monitor therapy

Upadacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Upadacitinib. Risk X: Avoid combination

Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 2 to 3 months after therapy is complete. Risk D: Consider therapy modification

Vaccines (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Live). Risk X: Avoid combination

Vedolizumab: Anti-TNF Agents may enhance the adverse/toxic effect of Vedolizumab. Risk X: Avoid combination

Yellow Fever Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. Risk X: Avoid combination

Reproductive Considerations

The American Academy of Dermatology considers tumor necrosis factor (TNF) blocking agents for the treatment of psoriasis to be compatible for use in patients planning to father a child (AAD-NPF [Menter 2019]). Patients with psoriasis planning to become pregnant may continue treatment with adalimumab. Patients with well-controlled psoriasis who wish to avoid fetal exposure can consider discontinuing adalimumab 10 weeks prior to attempting to become pregnant (Rademaker 2018).

Biologics, such as adalimumab, may be continued in patients with inflammatory bowel disease (eg, Crohn disease, ulcerative colitis) planning to become pregnant (Mahadevan 2019). Treatment algorithms are available for use of biologics in patients with Crohn disease who are planning to become pregnant (Weizman 2019).

Pregnancy Considerations

Adalimumab crosses the placenta.

Adalimumab is a humanized monoclonal antibody (IgG1). Placental transfer of human IgG is dependent upon the IgG subclass, maternal serum concentrations, birth weight, and gestational age, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis (Palmeira 2012; Pentsuk 2009).

Following administration to pregnant patients with inflammatory bowel disease (eg, Crohn disease, ulcerative colitis), cord blood and newborn serum concentrations of adalimumab are greater than maternal serum at delivery (Julsgaard 2016; Mahadevan 2013). The mean time to adalimumab clearance was 4 months (range: 2.9 to 5 months) in a study in 36 infants exposed in utero. The estimated mean half-life of adalimumab in these infants was 26 days (Julsgaard 2016). One case report notes adalimumab was detectable in the infant serum for 19 months following in utero exposure (Labetoulle 2018).

Based on available data, an increased risk of adverse maternal or fetal effects has not been observed following adalimumab exposure during pregnancy (Nielsen 2020). Adalimumab information from a pregnancy registry collected between 2004 and 2016 is available. Included were pregnant women with rheumatoid arthritis (RA) or Crohn disease (CD) treated with adalimumab at least during the first trimester (n=257), pregnant women with RA or CD not treated with adalimumab (disease untreated control, n=120), and pregnant women without RA or CD (healthy unexposed control, n=225); 42 cases lost to follow-up. The incidence of major birth defects was not significantly different between the study groups and no pattern of specific defects was observed. An increased risk of growth restriction or serious opportunistic infections was not associated with maternal adalimumab therapy when compared to the disease untreated controls. An increased risk of preterm delivery was observed in pregnant patients with RA or CD, regardless of adalimumab exposure (Chambers 2019). Information related to this class of medications is emerging, but based on available data, tumor necrosis factor alpha (TNFα) blocking agents are considered to have low to moderate risk when used in pregnancy (ACOG 776 2019).

The risk of immunosuppression may be increased following third trimester maternal use of TNFα blocking agents; the fetus, neonate/infant should be considered immunosuppressed for 1 to 3 months following in utero exposure (AAD-NPF [Menter 2019]). Vaccination with live vaccines (eg, rotavirus vaccine) should be avoided for the first 6 months of life if exposure to a biologic agent occurs during the third trimester of pregnancy (eg, >27 weeks' gestation) (Mahadevan 2019).

Maternal adalimumab serum concentrations remain stable as pregnancy progresses (Flanagan 2020; Seow 2017).

Inflammatory bowel disease is associated with adverse pregnancy outcomes including an increased risk of miscarriage, premature delivery, delivery of a low birth weight infant, and poor maternal weight gain. Management of maternal disease should be optimized prior to pregnancy. Treatment decreases disease flares, disease activity, and the incidence of adverse pregnancy outcomes (Mahadevan 2019).

Use of immune modulating therapies in pregnancy should be individualized to optimize maternal disease and pregnancy outcomes (ACOG 776 2019). The American Academy of Dermatology considers TNFα blocking agents for the treatment of psoriasis to be compatible with pregnancy (AAD-NPF [Menter 2019]). When treatment for inflammatory bowel disease is needed in pregnant women, appropriate biologic therapy can be continued without interruption. Serum levels should be evaluated prior to conception and optimized to avoid subtherapeutic concentrations or high levels which may increase placental transfer. Dosing can be adjusted so delivery occurs at the lowest serum concentration. For adalimumab, the final injection can be given 2 to 3 weeks prior to the estimated date of delivery (1 to 2 weeks if weekly dosing), then continued 48 hours postpartum (Mahadevan 2019).

Data collection to monitor pregnancy and infant outcomes following exposure to adalimumab is ongoing. Women exposed to adalimumab during pregnancy for the treatment of an autoimmune disease (eg, inflammatory bowel disease) may contact the OTIS Autoimmune Diseases Study at 877-311-8972.

Monitoring Parameters

Monitor improvement of symptoms and physical function assessments. Latent TB screening prior to initiating and during therapy; signs/symptoms of infection (prior to, during, and following therapy); CBC with differential; signs/symptoms/worsening of heart failure; LFTs at baseline; HBV screening prior to initiating (all patients), HBV carriers (during and for several months following therapy); signs and symptoms of hypersensitivity reaction; symptoms of lupus-like syndrome; signs/symptoms of malignancy (eg, splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss), including periodic skin examination.

Reference Range

Crohn disease (ECCO/ESPGHAN [van Rheenen 2020]): Early proactive therapeutic monitoring is recommended to optimize dose and prevent underdosing in pediatric Crohn disease patients.

Timing of serum sample: Prior to third injection (4 weeks after first dose).

Therapeutic concentrations: 7.5 to 10 mcg/mL.

Mechanism of Action

Adalimumab is a recombinant monoclonal antibody that binds to human tumor necrosis factor alpha (TNF-alpha), thereby interfering with binding to TNFα receptor sites and subsequent cytokine-driven inflammatory processes. Elevated TNF levels in the synovial fluid are involved in the pathologic pain and joint destruction in immune-mediated arthritis. Adalimumab decreases signs and symptoms of psoriatic arthritis, rheumatoid arthritis, and ankylosing spondylitis. It inhibits progression of structural damage of rheumatoid and psoriatic arthritis. Reduces signs and symptoms and maintains clinical remission in Crohn disease and ulcerative colitis; reduces epidermal thickness and inflammatory cell infiltration in plaque psoriasis.

Pharmacokinetics (Adult Data Unless Noted)

Onset of action: Response best determined after 3 to 4 months (AAD-NPF [Menter 2019]).

Distribution: Vd: 4.7 to 6 L; Synovial fluid concentrations: 31% to 96% of serum

Bioavailability: Absolute: 64%

Half-life elimination: Terminal: ~2 weeks (range: 10 to 20 days)

Time to peak, serum: SUBQ: 131 ± 56 hours

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Older adult: In patients with rheumatoid arthritis (RA), there was a trend toward lower clearance with increasing age in patients 40 to >75 years of age.

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Amgevita | Humira | Hyrimoz;
  • (AR) Argentina: Amgevita | Humira | Humira ac;
  • (AT) Austria: Amgevita | Hukyndra | Hulio | Humira | Hyrimoz | Idacio | Imraldi | Yuflyma;
  • (AU) Australia: Amgevita | Hadlima | Humira | Hyrimoz | Idacio | Yuflyma;
  • (BE) Belgium: Amgevita | Amsparity | Hukyndra | Hulio | Humira | Hyrimoz | Idacio | Imraldi | Yuflyma;
  • (BG) Bulgaria: Amgevita | Hukyndra | Hulio | Humira | Hyrimoz | Yuflyma;
  • (BR) Brazil: Amgevita | Humira | Hyrimoz | Idacio | Xilbrilada;
  • (CH) Switzerland: Abrilada | Amgevita | Hulio | Humira | Hyrimoz | Idacio | Imraldi;
  • (CL) Chile: Amgevita | Humira | Humira ac | Hyrimoz | Idacio;
  • (CN) China: Humira | Sulinno;
  • (CO) Colombia: Abrilada | Amgevita | Humira | Humira ac | Hyrimoz | Idacio;
  • (CZ) Czech Republic: Amgevita | Hukyndra | Hulio | Humira | Hyrimoz | Idacio | Imraldi | Yuflyma;
  • (DE) Germany: Amgevita | Cyltezo | Hukyndra | Hulio | Humira | Hyrimoz | Idacio | Imraldi | Kromeya | Libmyris | Yuflyma;
  • (DK) Denmark: Humira;
  • (DO) Dominican Republic: Humira | Humira ac;
  • (EC) Ecuador: Amgevita | Humira ac | Hyrimoz;
  • (EE) Estonia: Amgevita | Hukyndra | Hulio | Humira | Hyrimoz | Idacio | Imraldi;
  • (EG) Egypt: Amgevita | Humira | Hyrimoz;
  • (ES) Spain: Amgevita | Hulio | Humira | Hyrimoz | Idacio | Imraldi | Yuflyma;
  • (FI) Finland: Amgevita | Hukyndra | Hulio | Humira | Hyrimoz | Idacio | Imraldi | Yuflyma;
  • (FR) France: Amgevita | Amsparity | Hukyndra | Hulio | Humira | Hyrimoz | Idacio | Imraldi | Yuflyma;
  • (GB) United Kingdom: Amgevita | Hulio | Humira | Hyrimoz | Idacio | Imraldi | Yuflyma;
  • (GR) Greece: Amgevita | Hefiya | Hulio | Humira | Hyrimoz | Idacio | Imraldi | Yuflyma;
  • (HK) Hong Kong: Amgevita | Humira | Hyrimoz;
  • (HR) Croatia: Amgevita | Hulio | Humira | Hyrimoz | Imraldi;
  • (HU) Hungary: Amgevita | Hulio | Humira | Idacio | Yuflyma;
  • (ID) Indonesia: Humira;
  • (IE) Ireland: Amgevita | Cyltezo | Halimatoz | Hefiya | Hulio | Humira | Hyrimoz | Idacio | Imraldi | Yuflyma;
  • (IN) India: Adalipca | Adalirel | Adaly | Adfrar | Adlumab | Amab | Cadalimab | Envira | Exemptia | Mabura | Plamumab;
  • (IT) Italy: Amgevita | Humira | Hyrimoz | Idacio | Imraldi | Yuflyma;
  • (JO) Jordan: Amgevita | Humira | Hyrimoz;
  • (JP) Japan: Humira;
  • (KE) Kenya: Adalirel | Pamera;
  • (KR) Korea, Republic of: Adalloce | Humira;
  • (KW) Kuwait: Humira | Hyrimoz;
  • (LB) Lebanon: Amgevita | Cinnora | Humira | Hyrimoz;
  • (LT) Lithuania: Amgevita | Hukyndra | Hulio | Humira | Hyrimoz | Idacio | Imraldi | Yuflyma;
  • (LU) Luxembourg: Amgevita | Hulio | Humira | Hyrimoz | Imraldi | Yuflyma;
  • (LV) Latvia: Hukyndra | Hulio | Humira | Hyrimoz | Idacio | Imraldi | Yuflyma;
  • (MA) Morocco: Humira;
  • (MX) Mexico: Humira | Humira ac | Hyrimoz;
  • (MY) Malaysia: Amgevita | Idacio;
  • (NL) Netherlands: Amgevita | Hukyndra | Hulio | Humira | Hyrimoz | Idacio | Imraldi | Yuflyma;
  • (NO) Norway: Humira | Hyrimoz | Imraldi;
  • (NZ) New Zealand: Amgevita;
  • (PE) Peru: Amgevita | Humira;
  • (PH) Philippines: Humira;
  • (PL) Poland: Amgevita | Hulio | Humira | Hyrimoz | Imraldi;
  • (PR) Puerto Rico: Humira;
  • (PT) Portugal: Amgevita | Hulio | Humira | Hyrimoz | Idacio | Imraldi;
  • (PY) Paraguay: Amgevita | Humira | Humira ac;
  • (QA) Qatar: Amgevita | Amgevita Sureclick | Hadlima | Hulio | Humira | Hyrimoz | Hyrimoz Sensoready;
  • (RO) Romania: Amgevita | Hukyndra | Hulio | Humira | Hyrimoz | Idacio | Imraldi;
  • (RU) Russian Federation: Dalibra | Humira;
  • (SA) Saudi Arabia: Abrilada | Amgevita | Hadlima;
  • (SE) Sweden: Amgevita | Hukyndra | Hulio | Humira | Hyrimoz | Idacio | Imraldi;
  • (SG) Singapore: Amgevita | Humira;
  • (SI) Slovenia: Amgevita | Hukyndra | Hulio | Humira | Hyrimoz | Idacio | Imraldi;
  • (SK) Slovakia: Amgevita | Hukyndra | Hulio | Humira | Hyrimoz | Idacio | Yuflyma;
  • (TH) Thailand: Abrilada | Humira;
  • (TN) Tunisia: Humira;
  • (TR) Turkey: Amgevita | Humira;
  • (TW) Taiwan: Amgevita | Idacio;
  • (UA) Ukraine: Hadlima | Humira | Hyrimoz;
  • (UY) Uruguay: Humira | Humira ac | Hyrimoz;
  • (ZA) South Africa: Amgevita | Hulio | Humira | Hyrimoz
  1. A-Rahim YI, Farrell RJ. Overview of dosing and monitoring of biologic agents and small molecules for treating ulcerative colitis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com. Accessed May 4, 2021.
  2. Abrilada (adalimumab-afzb) [prescribing information]. New York, NY: Pfizer Inc; October 2023.
  3. Abrilada (adalimumab) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; April 2021.
  4. Adalimumab injection [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; January 2021.
  5. Adar T, Mizrahi M, Pappo O, Scheiman-Elazary A, Shibolet O. Adalimumab-induced autoimmune hepatitis. J Clin Gastroenterol. 2010;44(1):e20-e22. doi:10.1097/MCG.0b013e3181a745e7 [PubMed 19593165]
  6. Ai JW, Zhang S, Ruan QL, et al. The risk of tuberculosis in patients with rheumatoid arthritis treated with tumor necrosis factor-α antagonist: a metaanalysis of both randomized controlled trials and registry/cohort studies. J Rheumatol. 2015;42(12):2229-2237. doi:10.3899/jrheum.150057 [PubMed 26472414]
  7. Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597. [PubMed 3960626]
  8. Amarante CF, Acedo LM, Rabay FM, Campos Bdo E, Lira ML, Mandelbaum SH. Drug-induced lupus with leukocytoclastic vasculitis: a rare expression associated with adalimumab. An Bras Dermatol. 2015;90(3 suppl 1):121-124. doi:10.1590/abd1806-4841.20153834 [PubMed 26312693]
  9. American College of Obstetricians and Gynecologists (ACOG). Committee opinion no. 776: immune modulating therapies in pregnancy and lactation. Obstet Gynecol. 2019;133(4):e287-e295. [PubMed 30913201]
  10. Amgevita (adalimumab) [product monograph]. Mississauga, Ontario, Canada: Amgen Canada Inc; July 2021.
  11. Amjevita (adalimumab) [prescribing information]. Thousand Oaks, CA: Amgen Inc; August 2023.
  12. Angel K, Provan SA, Gulseth HL, Mowinckel P, Kvien TK, Atar D. Tumor necrosis factor-alpha antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study. Hypertension. 2010;55(2):333-338. doi:10.1161/HYPERTENSIONAHA.109.143982 [PubMed 20038753]
  13. Arts EE, Fransen J, den Broeder AA, Popa CD, van Riel PL. The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients. Ann Rheum Dis. 2015;74(6):998-1003. doi:10.1136/annrheumdis-2013-204531 [PubMed 24458537]
  14. Askling J, Baecklund E, Granath F, et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis. 2009;68(5):648-653. doi:10.1136/ard.2007.085852 [PubMed 18467516]
  15. Askling J, Fored CM, Brandt L, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis. 2005;64(10):1421-1426. doi:10.1136/ard.2004.033993 [PubMed 15829572]
  16. Averbukh LD, Wu GY. Role of biologics in the development of autoimmune hepatitis: a review. J Clin Transl Hepatol. 2018;6(4):402-409. doi:10.14218/JCTH.2018.00039 [PubMed 30637218]
  17. Bae JM, Kwon HS, Kim GM, Park KS, Kim KJ. Paradoxical psoriasis following anti-TNF therapy in ankylosing spondylitis: a population-based cohort study. J Allergy Clin Immunol. 2018;142(3):1001-1003.e2. doi:10.1016/j.jaci.2018.05.015 [PubMed 29859201]
  18. Bae JM, Lee HH, Lee BI, et al. Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study. Aliment Pharmacol Ther. 2018;48(2):196-205. doi:10.1111/apt.14822 [PubMed 29869804]
  19. Barešić M, Reihl Crnogaj M, Zadro I, Anić B. Demyelinating disease (multiple sclerosis) in a patient with psoriatic arthritis treated with adalimumab: a case-based review. Rheumatol Int. 2021;41(12):2233-2239. doi:10.1007/s00296-021-04995-0 [PubMed 34557936]
  20. Baughman RP, Valeyre D, Korsten P, et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J. 2021;58(6):2004079. doi:10.1183/13993003.04079-2020 [PubMed 34140301]
  21. Baumgart DC, Grittner U, Steingräber A, Azzaro M, Philipp S. Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: experience from a consecutive cohort of inflammatory bowel disease patients. Inflamm Bowel Dis. 2011;17(12):2512-2520. doi:10.1002/ibd.21643 [PubMed 21351201]
  22. Bavbek S, Ataman Ş, Akıncı A, Castells M. Rapid subcutaneous desensitization for the management of local and systemic hypersensitivity reactions to etanercept and adalimumab in 12 patients. J Allergy Clin Immunol Pract. 2015;3(4):629-632. doi:10.1016/j.jaip.2015.01.009 [PubMed 25725941]
  23. Bavbek S, Ataman Ş, Bankova L, Castells M. Injection site reaction to adalimumab: positive skin test and successful rapid desensitisation. Allergol Immunopathol (Madr). 2013;41(3):204-206. doi:10.1016/j.aller.2012.04.006 [PubMed 23063342]
  24. Ben-Horin S, Yavzori M, Katz L, et al. Adalimumab level in breast milk of a nursing mother. Clin Gastroenterol Hepatol. 2010;8(5):475-476. [PubMed 20005982]
  25. Benucci M, Manfredi M, Demoly P, Campi P. Injection site reactions to TNF-alpha blocking agents with positive skin tests. Allergy. 2008;63(1):138-139. doi:10.1111/j.1398-9995.2007.01536.x [PubMed 18053024]
  26. Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. Clin Pharmacokinet. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7 [PubMed 29441476]
  27. Björnsson ES, Gunnarsson BI, Gröndal G, et al. Risk of drug-induced liver injury from tumor necrosis factor antagonists. Clin Gastroenterol Hepatol. 2015;13(3):602-608. doi:10.1016/j.cgh.2014.07.062 [PubMed 25131534]
  28. Björnsson HK, Gudbjornsson B, Björnsson ES. Infliximab-induced liver injury: clinical phenotypes, autoimmunity and the role of corticosteroid treatment. J Hepatol. 2022;76(1):86-92. doi:10.1016/j.jhep.2021.08.024 [PubMed 34487751]
  29. Boggs JME, Ramsay B, Lynch M. Paradoxical psoriasis caused by tumour necrosis factor inhibitor therapy. Clin Exp Dermatol. 2021;46(3):580-582. doi:10.1111/ced.14500 [PubMed 33151572]
  30. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295(19):2275-2285. doi:10.1001/jama.295.19.2275 [PubMed 16705109]
  31. Burgos-Vargas R, Tse SM, Horneff G, et al. A randomized, double-blind, placebo-controlled multicenter study of adalimumab in pediatric patients with enthesitis-related arthritis. Arthritis Care Res (Hoboken). 2015;67(11):1503-1512. [PubMed 26223543]
  32. Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis. 2013;72(4):517-524. doi:10.1136/annrheumdis-2011-201244 [PubMed 22562972]
  33. Canu D, Seneschal J, Milpied B, Taieb A, Darrigade AS. TNFα inhibitor-induced urticaria: a class effect. Eur J Dermatol. 2019;29(5):543-544. doi:10.1684/ejd.2019.3625 [PubMed 31789277]
  34. Centers for Disease Control and Prevention (CDC). Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep. 2000;49(RR-6):1-51. [PubMed 10881762]
  35. Centers for Disease Control and Prevention (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 1984;33(14):198-199. http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm [PubMed 6423951]
  36. Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109(7):950-966. [PubMed 24935270]
  37. Chalasani NP, Maddur H, Russo MW, Wong RJ, Reddy KR; Practice Parameters Committee of the American College of Gastroenterology. ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2021;116(5):878-898. doi:10.14309/ajg.0000000000001259 [PubMed 33929376]
  38. Chambers CD, Johnson DL, Xu R, et al; OTIS Collaborative Research Group. Birth outcomes in women who have taken adalimumab in pregnancy: a prospective cohort study. PLoS One. 2019;14(10):e0223603. doi:10.1371/journal.pone.0223603 [PubMed 31626646]
  39. Chen HK, Shao SC, Weng MY, et al. Risk of heart failure in rheumatoid arthritis patients treated with tumor necrosis factor-α inhibitors. Clin Pharmacol Ther. 2021;110(6):1595-1603. doi:10.1002/cpt.2415 [PubMed 34496051]
  40. Choi SJ, Ahn SM, Oh JS, et al. Anti-tumor necrosis factor-induced lupus in patients with inflammatory bowel disease: a hospital-based cohort study from Korea. Therap Adv Gastroenterol. 2021;14:1756284821997794. doi:10.1177/1756284821997794 [PubMed 33747126]
  41. Choi SJ, Oh JS, Hong S, Lee CK, Yoo B, Kim YG. Liver enzyme elevation in patients with ankylosing spondylitis treated with tumor necrosis factor inhibitors: a single-center historical cohort study. Korean J Intern Med. 2020;35(3):723-731. doi:10.3904/kjim.2018.407 [PubMed 31870134]
  42. Colombel JF, Schwartz DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut. 2009;58(7):940-948. doi: 10.1136/gut.2008.159251. [PubMed 19201775]
  43. Conti F, Atzeni F, Massaro L, et al. The influence of comorbidities on the efficacy of tumour necrosis factor inhibitors, and the effect of tumour necrosis factor inhibitors on comorbidities in rheumatoid arthritis: report from a National Consensus Conference. Rheumatology (Oxford). 2018;57(57 suppl 7):vii11-vii22. doi:10.1093/rheumatology/key209 [PubMed 30289537]
  44. Coşkun BN, Yağız B, Çorabay SG, Pehlivan Y, Dalkılıç E. Anti-TNF treatment in ankylosing spondylitis patients with chronic kidney disease: Is it effective and safe? Eur J Rheumatol. 2022;9(2):68-74. doi:10.5152/eurjrheum.2022.21099. [PubMed 35546331]
  45. Cossio ML, Genois A, Jantchou P, Hatami A, Deslandres C, McCuaig C. Skin manifestations in pediatric patients treated with a TNF-alpha inhibitor for inflammatory bowel disease: a retrospective study. J Cutan Med Surg. 2020;24(4):333-339. doi:10.1177/1203475420917387 [PubMed 32527153]
  46. Crommelin HA, van der Burg LM, Vorselaars AD, et al. Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab. Respir Med. 2016;115:72-77. doi:10.1016/j.rmed.2016.04.011 [PubMed 27215507]
  47. Crowson CS, Liao KP, Davis JM 3rd, et al. Rheumatoid arthritis and cardiovascular disease. Am Heart J. 2013;166(4):622-628.e1. doi:10.1016/j.ahj.2013.07.010 [PubMed 24093840]
  48. Cyltezo (adalimumab) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; June 2023.
  49. Cyrenne BM, Parpia AS, Sibbald C. Paradoxical psoriasis in pediatric patients: a systematic review. Pediatr Dermatol. 2021;38(5):1086-1093. doi:10.1111/pde.14712 [PubMed 34402108]
  50. Darrigade AS, Milpied B, Truchetet ME, et al. Pattern and severity of psoriasiform eruptions in patients with inflammatory bowel diseases, arthritis or skin inflammatory disorders treated with TNF-alpha inhibitors. Acta Derm Venereol. 2017;97(6):731-734. doi:10.2340/00015555-2636 [PubMed 28218339]
  51. Davies HD, Committee on Infectious Disease. Infectious complications with the use of biologic response modifiers in infants and children. Pediatrics. 2016;138(2):e20161209. [PubMed 27432853]
  52. De Wet J, Jordaan HF, Kannenberg SM, Tod B, Glanzmann B, Visser WI. Pyoderma gangrenosum, acne, and suppurative hidradenitis syndrome in end-stage renal disease successfully treated with adalimumab. Dermatol Online J. 2017;23(12):13030/qt82d4m2zw. [PubMed 29447652]
  53. Drent M, Cremers JP, Jansen TL, Baughman RP. Practical eminence and experience-based recommendations for use of TNF-α inhibitors in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(2):91-107. [PubMed 25078637]
  54. Dubinsky MC, Rosh J, Faubion WA Jr, et al. Efficacy and safety of escalation of adalimumab therapy to weekly dosing in pediatric patients with Crohn's disease. Inflamm Bowel Dis. 2016;22(4):886-893. [PubMed 26950307]
  55. Eickstaedt JB, Killpack L, Tung J, Davis D, Hand JL, Tollefson MM. Psoriasis and psoriasiform eruptions in pediatric patients with inflammatory bowel disease treated with anti-tumor necrosis factor alpha agents. Pediatr Dermatol. 2017;34(3):253-260. doi:10.1111/pde.13081 [PubMed 28211161]
  56. Eissner G, Kirchner S, Lindner H, et al. Reverse signaling through transmembrane TNF confers resistance to lipopolysaccharide in human monocytes and macrophages. J Immunol. 2000;164(12):6193-6198. doi:10.4049/jimmunol.164.12.6193 [PubMed 10843670]
  57. Engel S, Luessi F, Mueller A, Schopf RE, Zipp F, Bittner S. PPMS onset upon adalimumab treatment extends the spectrum of anti-TNF-α therapy-associated demyelinating disorders. Ther Adv Neurol Disord. 2020;13:1756286419895155. doi:10.1177/1756286419895155 [PubMed 31921355]
  58. Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.
  59. Faivre C, Villani AP, Aubin F, et al. Hidradenitis suppurativa (HS): an unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases. J Am Acad Dermatol. 2016;74(6):1153-1159. doi:10.1016/j.jaad.2016.01.018 [PubMed 26965410]
  60. Fernández-Crehuet P, Ruiz-Villaverde R. Acneiform eruption as a probable paradoxical reaction to adalimumab. Int J Dermatol. 2015;54(8):e306-e308. doi:10.1111/ijd.12416 [PubMed 24697221]
  61. Feuerstein JD, Cheifetz AS. Miscellaneous adverse events with biologic agents (excludes infection and malignancy). Gastroenterol Clin North Am. 2014;43(3):543-563. doi:10.1016/j.gtc.2014.05.002 [PubMed 25110258]
  62. Feuerstein JD, Ho EY, Shmidt E, et al; American Gastroenterological Association Institute Clinical Guidelines Committee. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease. Gastroenterology. 2021;160(7):2496-2508. doi:10.1053/j.gastro.2021.04.022 [PubMed 34051983]
  63. Feuerstein JD, Nguyen GC, Kupfer SS, Falck-Ytter Y, Singh S; American Gastroenterological Association Institute Clinical Guidelines Committee. American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterology. 2017;153(3):827-834. doi: 10.1053/j.gastro.2017.07.032. [PubMed 28780013]
  64. Flanagan E, Gibson PR, Wright EK, et al; PICCOLO Study Group. Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure. Aliment Pharmacol Ther. 2020;52(10):1551-1562. doi:10.1111/apt.16102 [PubMed 32981127]
  65. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021;73(7):924-939. doi:10.1002/acr.24596 [PubMed 34101387]
  66. French JB, Bonacini M, Ghabril M, Foureau D, Bonkovsky HL. Hepatotoxicity associated with the use of anti-TNF-α agents. Drug Saf. 2016;39(3):199-208. doi:10.1007/s40264-015-0366-9 [PubMed 26692395]
  67. Frider B, Bruno A, Ponte M, Amante M. Drug-induced liver injury caused by adalimumab: a case report and review of the bibliography. Case Reports Hepatol. 2013;2013:406901. doi:10.1155/2013/406901 [PubMed 25431703]
  68. Fritzsche J, Pilch A, Mury D, Schaefer C, Weber-Schoendorfer C. Infliximab and adalimumab use during breastfeeding. J Clin Gastroenterol. 2012;46(8):718-719. [PubMed 22858514]
  69. Furst DE, Keystone EC, Braun J, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. Ann Rheum Dis. 2011;70(suppl 1):s2-s36. doi:10.1136/ard.2010.146852 [PubMed 21339216]
  70. Gallagher M, Quinones K, Cervantes-Castañeda RA, Yilmaz T, Foster CS. Biological response modifier therapy for refractory childhood uveitis. Br J Ophthalmol. 2007;91(10):1341-1344. [PubMed 17556427]
  71. Ghabril M, Bonkovsky HL, Kum C, et al. Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol. 2013;11(5):558-564.e3. doi:10.1016/j.cgh.2012.12.025 [PubMed 23333219]
  72. Gilotra NA, Wand AL, Pillarisetty A, et al. Clinical and imaging response to tumor necrosis factor alpha inhibitors in treatment of cardiac sarcoidosis: a multicenter experience. J Card Fail. 2021;27(1):83-91. doi:10.1016/j.cardfail.2020.08.013 [PubMed 32889044]
  73. Godfrey MS, Friedman LN. Tuberculosis and biologic therapies: anti-tumor necrosis factor-α and beyond. Clin Chest Med. 2019;40(4):721-739. doi:10.1016/j.ccm.2019.07.003 [PubMed 31731980]
  74. González-Cuevas R, Peruilh-Bagolini L, Valenzuela F, Vargas-Mora P. Cutaneous lupus erythematosus induced by adalimumab: a case report. Dermatol Ther. 2020;33(6):e14339. doi:10.1111/dth.14339 [PubMed 32975341]
  75. Goodman SM, Springer BD, Chen AF, et al. 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty. Arthritis Care Res (Hoboken). 2022;74(9):1399-1408. doi:10.1002/acr.24893 [PubMed 35718887]
  76. Grace E, Goldblum O, Renda L, et al. Injection site reactions in the Federal Adverse Event Reporting System (FAERS) post-marketing database vary among biologics approved to treat moderate-to-severe psoriasis. Dermatol Ther (Heidelb). 2020;10(1):99-106. doi:10.1007/s13555-019-00341-2 [PubMed 31734937]
  77. Grasland A, Sterpu R, Boussoukaya S, Mahe I. Autoimmune hepatitis induced by adalimumab with successful switch to abatacept. Eur J Clin Pharmacol. 2012;68(5):895-898. doi:10.1007/s00228-011-1191-4 [PubMed 22205272]
  78. Grijalva CG, Chen L, Delzell E, et al. Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA. 2011;306(21):2331-2339. doi:10.1001/jama.2011.1692 [PubMed 22056398]
  79. Gulsen A, Wedi B, Jappe U. Hypersensitivity reactions to biologics (part II): classifications and current diagnostic and treatment approaches. Allergo J Int. 2020;29:139-154. doi:10.1007/s40629-020-00127-5
  80. Hadlima (adalimumab-bwwd) [prescribing information]. Jersey City, NJ: Organon LLC; July 2023.
  81. Hadlima and Hadlima PushTouch (adalimumab) [product monograph]. Kirkland, Quebec, Canada: Organon Canada Inc; December 2022.
  82. Hammam N, Evans M, Morgan E, et al. Treatment of sarcoidosis in US rheumatology practices: data from the American College of Rheumatology's Rheumatology Informatics System for Effectiveness (RISE) Registry. Arthritis Care Res (Hoboken). 2022;74(3):371-376. doi:10.1002/acr.24496 [PubMed 33105057]
  83. Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol. 2006;33(11):2167-2172. [PubMed 16981296]
  84. Hansel K, Bianchi L, Tramontana M, et al. Immediate local and systemic hypersensitivity due to etanercept and adalimumab. J Allergy Clin Immunol Pract. 2019;7(2):726-727. doi:10.1016/j.jaip.2018.06.020 [PubMed 30006049]
  85. Hawryluk EB, Linskey KR, Duncan LM, Nazarian RM. Broad range of adverse cutaneous eruptions in patients on TNF-alpha antagonists. J Cutan Pathol. 2012;39(5):481-492. doi:10.1111/j.1600-0560.2012.01894.x [PubMed 22515220]
  86. Her M, Kavanaugh A. Alterations in immune function with biologic therapies for autoimmune disease. J Allergy Clin Immunol. 2016;137(1):19-27. doi:10.1016/j.jaci.2015.10.023 [PubMed 26768759]
  87. Hohlfeld R. Inhibitors of tumor necrosis factor-alpha: promising agents for the treatment of multiple sclerosis? Mult Scler. 1996;1(6):376-378. doi:10.1177/135245859600100619 [PubMed 9345421]
  88. Hueber AJ, Tunc A, Schett G, Manger B. Anti-tumour necrosis factor alpha therapy in patients with impaired renal function. Ann Rheum Dis. 2007;66(7):981-982. doi:10.1136/ard.2006.069211 [PubMed 17337474]
  89. Hulio (adalimumab-fkjp) [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; August 2023.
  90. Hulio (adalimumab) [product monograph]. Etobicoke, Ontario, Canada: BGP Pharma ULC; July 2023.
  91. Humira (adalimumab) [prescribing information]. North Chicago, IL: AbbVie Inc; November 2023.
  92. Humira (adalimumab) [product monograph]. St-Laurent, Quebec, Canada: AbbVie Corporation; March 2018.
  93. Humira (adalimumab) [product monograph]. St-Laurent, Quebec, Canada: AbbVie Corporation; September 2022.
  94. Hutto SK, Rice DR, Mateen FJ. CNS demyelination with TNFα inhibitor exposure: a retrospective cohort study. J Neuroimmunol. 2021;356:577587. doi:10.1016/j.jneuroim.2021.577587 [PubMed 33945946]
  95. Hyams JS, Griffiths A, Markowitz J, et al. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children. Gastroenterology. 2012;143(2):365-374. [PubMed 22562021]
  96. Hyrimoz (adalimumab-adaz) [prescribing information]. Princeton, NJ: Sandoz Inc; September 2023.
  97. Hyrimoz (adalimumab) [product monograph]. Boucherville, Québec, Canada: Sandoz Canada Inc; September 2021.
  98. Idacio (adalimumab) [prescribing information]. Lake Zurich, IL: Fresenius Kabi USA LLC; October 2023.
  99. Idacio (adalimumab) [product monograph]. Toronto, Ontario, Canada: Fresenius Kabi Canada Ltd; May 2022.
  100. Ingram JR. Hidradenitis suppurativa: management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com. Accessed July 19, 2023.
  101. Inoue A, Sawada Y, Yamaguchi T, et al. Lichenoid drug eruption caused by adalimumab: a case report and literature review. Eur J Dermatol. 2017;27(1):69-70. doi:10.1684/ejd.2016.2898 [PubMed 27777187]
  102. Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47(5):312-313. [PubMed 12534540]
  103. Juhász K, Buzás K, Duda E. Importance of reverse signaling of the TNF superfamily in immune regulation. Expert Rev Clin Immunol. 2013;9(4):335-348. doi:10.1586/eci.13.14 [PubMed 23557269]
  104. Julsgaard M, Christensen LA, Gibson PR, et al. Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection. Gastroenterology. 2016;151(1):110-119. [PubMed 27063728]
  105. Kalinowska-Lyszczarz A, Fereidan-Esfahani M, Guo Y, Lucchinetti CF, Tobin WO. Pathological findings in central nervous system demyelination associated with infliximab. Mult Scler. 2020;26(9):1124-1129. doi:10.1177/1352458519894710 [PubMed 31845616]
  106. Kelly D, O'Connell O, Henry M. Adalimumab-induced lupus serositis. BMJ Case Rep. 2015;2015:bcr2014207323. Published 2015 Mar 4. doi:10.1136/bcr-2014-207323 [PubMed 25739794]
  107. Kemanetzoglou E, Andreadou E. CNS Demyelination with TNF-α Blockers. Curr Neurol Neurosci Rep. 2017;17(4):36. doi:10.1007/s11910-017-0742-1 [PubMed 28337644]
  108. Kim E, Bressler B, Schaeffer DF, Yoshida EM. Severe cholestasis due to adalimumab in a Crohn's disease patient. World J Hepatol. 2013;5(10):592-595. doi:10.4254/wjh.v5.i10.592 [PubMed 24179620]
  109. Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375(5):422-434. doi:10.1056/NEJMoa1504370 [PubMed 27518661]
  110. Kingsbury DJ, Bader-Meunier B, Patel G, et al. Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years. Clin Rheumatol. 2014;33(10):1433–1441. [PubMed 24487484]
  111. Klarenbeek NB, van der Kooij SM, Huizinga TJ, et al. Blood pressure changes in patients with recent-onset rheumatoid arthritis treated with four different treatment strategies: a post hoc analysis from the BeSt trial. Ann Rheum Dis. 2010;69(7):1342-1345. doi:10.1136/ard.2009.124180 [PubMed 20472597]
  112. Kobak S. Efficacy and safety of adalimumab in a patient with ankylosing spondylitis on peritoneal dialysis. Rheumatol Int. 2012;32(6):1785-1787. doi:10.1007/s00296-010-1457-7 [PubMed 20340019]
  113. Kok B, Lester ELW, Lee WM, et al. Acute liver failure from tumor necrosis factor-α antagonists: report of four cases and literature review. Dig Dis Sci. 2018;63(6):1654-1666. doi:10.1007/s10620-018-5023-6 [PubMed 29564668]
  114. Koller T, Galambosova M, Filakovska S, et al. Drug-induced liver injury in inflammatory bowel disease: 1-year prospective observational study. World J Gastroenterol. 2017;23(22):4102-4111. doi:10.3748/wjg.v23.i22.4102 [PubMed 28652663]
  115. Kotyla PJ. Bimodal function of anti-TNF treatment: shall we be concerned about anti-TNF treatment in patients with rheumatoid arthritis and heart failure? Int J Mol Sci. 2018;19(6):1739. doi:10.3390/ijms19061739 [PubMed 29895751]
  116. Kumar N, Abboud H. Iatrogenic CNS demyelination in the era of modern biologics. Mult Scler. 2019;25(8):1079-1085. doi:10.1177/1352458519828601 [PubMed 30767720]
  117. Kunchok A, Aksamit AJ Jr, Davis JM 3rd, et al. Association between tumor necrosis factor inhibitor exposure and inflammatory central nervous system events. JAMA Neurol. 2020;77(8):937-946. doi:10.1001/jamaneurol.2020.1162 [PubMed 32421186]
  118. Kusakari Y, Yamasaki K, Takahashi T, et al. Successful adalimumab treatment of a psoriasis vulgaris patient with hemodialysis for renal failure: a case report and a review of the previous reports on biologic treatments for psoriasis patients with hemodialysis for renal failure. J Dermatol. 2015;42(7):727-730. doi:10.1111/1346-8138.12901 [PubMed 25916786]
  119. Kwon HJ, Coté TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med. 2003;138(10):807-811. doi:10.7326/0003-4819-138-10-200305200-00008 [PubMed 12755552]
  120. Labetoulle R, Roblin X, Paul S. Prolonged persistence of adalimumab transferred from mother to infant during pregnancy. Ann Intern Med. 2018;169(1):60-61. [PubMed 29507939]
  121. Lan JL, Chen YM, Hsieh TY, et al. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. Ann Rheum Dis. 2011;70(10):1719-1725. doi:10.1136/ard.2010.148783 [PubMed 21719446]
  122. Latus J, Klein R, Koetter I, et al. Cholestatic liver disease after rituximab and adalimumab and the possible role of cross-reacting antibodies to Fab 2 fragments. PLoS One. 2013;8(11):e78856. doi:10.1371/journal.pone.0078856 [PubMed 24244376]
  123. Lau G, Yu ML, Wong G, et al. APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy. Hepatol Int. 2021;15(5):1031-1048. doi:10.1007/s12072-021-10239-x [PubMed 34427860]
  124. Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis. 2009;68(7):1136-1145. doi:10.1136/ard.2008.091025 [PubMed 18753157]
  125. Li PH, Watts TJ, Lui MS, Lau CS, Chung HY. Recall urticaria in adalimumab hypersensitivity. J Allergy Clin Immunol Pract. 2018;6(3):1032-1033. doi:10.1016/j.jaip.2017.10.031 [PubMed 29175008]
  126. Li SJ, Perez-Chada LM, Merola JF. TNF Inhibitor-induced psoriasis: proposed algorithm for treatment and management. J Psoriasis Psoriatic Arthritis. 2019;4(2):70-80. doi:10.1177/2475530318810851 [PubMed 31093599]
  127. Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of Crohn's disease in adults. Am J Gastroenterol. 2018;113(4):481-517. doi: 10.1038/ajg.2018.27. [PubMed 29610508]
  128. Lieberman MR, Liebman TN, Alapati U, Khachemoune A. TNF-inhibitor induced lupus in a patient treated with adalimumab for rheumatoid arthritis. Dermatol Online J. 2014;21(2):13030/qt18r2916d. [PubMed 25756476]
  129. Lok ASF, Bonis PAL. Hepatitis B virus reactivation associated with immunosuppressive therapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com. Accessed September 31, 2021.
  130. Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology. 2017;152(6):1297-1309. doi:10.1053/j.gastro.2017.02.009 [PubMed 28219691]
  131. Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359(8):810-820. [PubMed 18716298]
  132. Lower EE, Sturdivant M, Grate L, Baughman RP. Use of third-line therapies in advanced sarcoidosis. Clin Exp Rheumatol. 2020;38(5):834-840. [PubMed 31820728]
  133. Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43(3):172. [PubMed 10985636]
  134. Mahadevan U, Martin CF, Sandler RS et al. PIANO: A 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy. Gastroenterology. 2012;142 (Suppl 1):S149.
  135. Mahadevan U, Robinson C, Bernasko N, et al. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American Gastroenterological Association IBD Parenthood Project Working Group. Am J Obstet Gynecol. 2019;220(4):308-323. doi:10.1016/j.ajog.2019.02.027 [PubMed 30948039]
  136. Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11(3):286-92; quiz e24. doi:10.1016/j.cgh.2012.11.011 [PubMed 23200982]
  137. Mansitó López C, Torres Laboy P, Ortiz Bou M, Quintero Noriega A, Cintron Rivera V. Fatal new-onset congestive heart failure related to adalimumab use in a patient with relapsing hidradenitis suppurativa: a case report. Am J Case Rep. 2021;22:e929148. doi:10.12659/AJCR.929148 [PubMed 33563886]
  138. Marzano AV, Tavecchio S, Berti E, Gelmetti C, Cugno M. Pustular skin reaction to tumor necrosis factor alpha antagonists in patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2015;21(11):E26-E27. doi:10.1097/MIB.0000000000000600 [PubMed 26422518]
  139. Massarotti M, Marasini B. Successful treatment with etanercept of a patient with psoriatic arthritis after adalimumab-related hepatotoxicity. Int J Immunopathol Pharmacol. 2009;22(2):547-549. doi:10.1177/039463200902200234 [PubMed 19505409]
  140. Matro R, Martin CF, Wolf D, Shah SA, Mahadevan U. Exposure concentrations of infants breastfed by women receiving biologic therapies for inflammatory bowel diseases and effects of breastfeeding on infections and development. Gastroenterology. 2018;155(3):696-704. [PubMed 29857090]
  141. Matsui T, Umetsu R, Kato Y, et al. Age-related trends in injection site reaction incidence induced by the tumor necrosis factor-α (TNF-α) inhibitors etanercept and adalimumab: the Food and Drug Administration adverse event reporting system, 2004-2015. Int J Med Sci. 2017;14(2):102-109. doi:10.7150/ijms.17025 [PubMed 28260984]
  142. Mease P, Sieper J, Van den Bosch F, Rahman P, Karunaratne PM, Pangan AL. Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis. Arthritis Rheumatol. 2015;67(4):914-923. doi:10.1002/art.39008 [PubMed 25545240]
  143. Melani AS, Bigliazzi C, Cimmino FA, Bergantini L, Bargagli E. A comprehensive review of sarcoidosis treatment for pulmonologists. Pulm Ther. 2021;7(2):325-344. doi:10.1007/s41030-021-00160-x [PubMed 34143362]
  144. Melo FJ, Magina S. Clinical management of Anti-TNF-alpha-induced psoriasis or psoriasiform lesions in inflammatory bowel disease patients: a systematic review. Int J Dermatol. 2018;57(12):1521-1532. doi:10.1111/ijd.14072 [PubMed 30028008]
  145. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029-1072. doi:10.1016/j.jaad.2018.11.057 [PubMed 30772098]
  146. Mercer LK, Lunt M, Low AL, et al. Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis. 2015;74(6):1087-1093. doi:10.1136/annrheumdis-2013-204851 [PubMed 24685910]
  147. Mocci G, Marzo M, Papa A, Armuzzi A, Guidi L. Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease. J Crohns Colitis. 2013;7(10):769-779. doi:10.1016/j.crohns.2013.01.009 [PubMed 23453887]
  148. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 2001;44(12):2862-2869. doi:10.1002/1529-0131(200112)44:12<2862::aid-art474>3.0.co;2-w [PubMed 11762947]
  149. Montolio Chiva L, Martínez Ferrer À, Mateu Puchades A, Campos Fernández C, Narváez Garcia J, Alegre Sancho JJ. Psoriasis induced by biological therapy. Reumatol Clin (Engl Ed). 2021;17(8):437-439. doi:10.1016/j.reumae.2020.06.003 [PubMed 34625145]
  150. Mounach A, Rezqi A, Nouijai A, et al. Stevens-Johnson syndrome complicating adalimumab therapy in rheumatoid arthritis disease. Rheumatol Int. 2013;33(5):1351-1353. doi:10.1007/s00296-011-2212-4 [PubMed 22187054]
  151. Moustou AE, Matekovits A, Dessinioti C, Antoniou C, Sfikakis PP, Stratigos AJ. Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review. J Am Acad Dermatol. 2009;61(3):486-504. doi:10.1016/j.jaad.2008.10.060 [PubMed 19628303]
  152. Murdaca G, Spanò F, Contatore M, et al. Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety? Expert Opin Drug Saf. 2016;15(1):43-52. doi:10.1517/14740338.2016.1112375 [PubMed 26559805]
  153. Murdaca G, Spanò F, Puppo F. Selective TNF-α inhibitor-induced injection site reactions. Expert Opin Drug Saf. 2013;12(2):187-193. doi:10.1517/14740338.2013.755957 [PubMed 23330811]
  154. Myasoedova E, Crowson CS, Kremers HM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis. 2011;70(3):482-487. doi:10.1136/ard.2010.135871 [PubMed 21216812]
  155. Nakamizo S, Miyachi Y, Kabashima K. Addition of cyclosporine to adalimumab improved psoriasis and adalimumab-induced injection site reaction. Indian J Dermatol. 2014;59(5):522-523. doi:10.4103/0019-5154.139924 [PubMed 25284873]
  156. Navarro-Millán I, Yang S, DuVall SL, et al. Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: data from the National Veterans Health Administration. Ann Rheum Dis. 2016;75(2):341-347. doi:10.1136/annrheumdis-2013-204987 [PubMed 25609412]
  157. Neves JM, Cunha N, Lencastre A, Cabete J. Paradoxical hidradenitis suppurativa to biologic agents: a case series and literature review. Int J Dermatol. 2019;58(11):e226-e228. doi:10.1111/ijd.14585 [PubMed 31290151]
  158. Nguyen GC, Loftus EV Jr, Hirano I, Falck-Ytter Y, Singh S, Sultan S; AGA Institute Clinical Guidelines Committee. American Gastroenterological Association Institute guideline on the management of Crohn's disease after surgical resection. Gastroenterology. 2017;152(1):271-275. doi:10.1053/j.gastro.2016.10.038 [PubMed 27840074]
  159. Nicola PJ, Maradit-Kremers H, Roger VL, et al. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum. 2005;52(2):412-420. doi:10.1002/art.20855 [PubMed 15692992]
  160. Nielsen OH, Gubatan JM, Juhl CB, Streett SE, Maxwell C. Biologics for inflammatory bowel disease and their safety in pregnancy: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2020:S1542-3565(20)31281-31287. doi:10.1016/j.cgh.2020.09.021 [PubMed 32931960]
  161. Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol. 2012;2012:985646. [PubMed 22235228]
  162. Paltiel M, Gober LM, Deng A, et al. Immediate type I hypersensitivity response implicated in worsening injection site reactions to adalimumab. Arch Dermatol. 2008;144(9):1190-1194. doi:10.1001/archderm.144.9.1190 [PubMed 18794465]
  163. Paramarta JE, De Rycke L, Heijda TF, et al. Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis. Ann Rheum Dis. 2013;72(11):1793-1799. doi:10.1136/annrheumdis-2012-202245 [PubMed 23139265]
  164. Parekh R, Kaur N. Liver injury secondary to anti-TNF-alpha therapy in inflammatory bowel disease: a case series and review of the literature. Case Rep Gastrointest Med. 2014;2014:956463. doi:10.1155/2014/956463 [PubMed 24707412]
  165. Pariser RJ, Paul J, Hirano S, Torosky C, Smith M. A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. J Am Acad Dermatol. 2013;68(5):765-773. doi:10.1016/j.jaad.2012.10.056 [PubMed 23276549]
  166. Pasadyn SR, Knabel D, Fernandez AP, Warren CB. Cutaneous adverse effects of biologic medications. Cleve Clin J Med. 2020;87(5):288-299. doi:10.3949/ccjm.87a.19119 [PubMed 32357984]
  167. Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res B Dev Reprod Toxicol. 2009;86(4):328-344. [PubMed 19626656]
  168. Picard M, Galvão VR. Current knowledge and management of hypersensitivity reactions to monoclonal antibodies. J Allergy Clin Immunol Pract. 2017;5(3):600-609. doi:10.1016/j.jaip.2016.12.001 [PubMed 28110056]
  169. Pugliese D, Guidi L, Ferraro PM, et al. Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study. Aliment Pharmacol Ther. 2015;42(7):880-888. doi:10.1111/apt.13352 [PubMed 26235565]
  170. Puxeddu I, Giori L, Rocchi V, et al. Hypersensitivity reactions during treatment with infliximab, etanercept, and adalimumab. Ann Allergy Asthma Immunol. 2012;108(2):123-124. doi:10.1016/j.anai.2011.11.004 [PubMed 22289732]
  171. Raaschou P, Frisell T, Askling J; ARTIS Study Group. TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis. 2015;74(12):2137-2143. doi:10.1136/annrheumdis-2014-205745 [PubMed 25107559]
  172. Rademaker M, Agnew K, Andrews M, et al. Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration. Australas J Dermatol. 2018;59(2):86-100. [PubMed 28543445]
  173. Ramos-Casals M, Brito-Zerón P, Muñoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore). 2007;86(4):242-251. doi:10.1097/MD.0b013e3181441a68 [PubMed 17632266]
  174. Ramos-Casals M, Roberto-Perez-Alvarez, Diaz-Lagares C, Cuadrado MJ, Khamashta MA; BIOGEAS Study Group. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev. 2010;9(3):188-193. doi:10.1016/j.autrev.2009.10.003 [PubMed 19854301]
  175. Refer to manufacturer's labeling.
  176. Rodrigues S, Lopes S, Magro F, et al. Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy: a single center report of 8 cases. World J Gastroenterol. 2015;21(24):7584-7588. doi:10.3748/wjg.v21.i24.7584 [PubMed 26140007]
  177. Rubin RL. Drug-induced lupus. Toxicology. 2005;209(2):135-147. doi:10.1016/j.tox.2004.12.025 [PubMed 15767026]
  178. Salomon BL, Leclerc M, Tosello J, Ronin E, Piaggio E, Cohen JL. Tumor necrosis factor α and regulatory T cells in oncoimmunology. Front Immunol. 2018;9:444. doi:10.3389/fimmu.2018.00444 [PubMed 29593717]
  179. Salvador-Rodriguez L, Montero-Vílchez T, Arias-Santiago S, Molina-Leyva A. Paradoxical hidradenitis suppurativa in patients receiving TNF-α inhibitors: case series, systematic review, and case meta-analysis. Dermatology. 2020;236(4):307-313. doi:10.1159/000506074 [PubMed 32135533]
  180. Schiff MH, Burmester GR, Kent JD, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65(7):889-894. doi:10.1136/ard.2005.043166 [PubMed 16439435]
  181. Sedger LM, McDermott MF. TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants - past, present and future. Cytokine Growth Factor Rev. 2014;25(4):453-472. doi:10.1016/j.cytogfr.2014.07.016 [PubMed 25169849]
  182. Seow CH, Leung Y, Vande Casteele N, et al. The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45(10):1329-1338. [PubMed 28318043]
  183. Seror R, Richez C, Sordet C, et al. Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey. Rheumatology (Oxford). 2013;52(5):868-874. doi:10.1093/rheumatology/kes375 [PubMed 23287362]
  184. Shah P, Sundaram V, Björnsson E. Biologic and checkpoint inhibitor-induced liver injury: a systematic literature review. Hepatol Commun. 2020;4(2):172-184. doi:10.1002/hep4.1465 [PubMed 32025603]
  185. Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313. [PubMed 7746084]
  186. Shelton E, Chaudrey K, Sauk J, et al. New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2015;41(10):972-979. doi:10.1111/apt.13159 [PubMed 25756190]
  187. Sieper J, van der Heijde D, Dougados M, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis. 2013;72(6):815-822. doi:10.1136/annrheumdis-2012-201766 [PubMed 22772328]
  188. Simlandi (adalimumab) [product monograph]. Boucherville, Quebec, Canada: Pfizer Canada ULC; December 2022.
  189. Simonini G, Taddio A, Cattalini M, et al. Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res (Hoboken). 2011;63(4):612-618. doi:10.1002/acr.20404 [PubMed 21452272]
  190. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(5):625-639. doi:10.1002/acr.21641 [PubMed 22473917]
  191. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;2011(2):CD008794. doi:10.1002/14651858.CD008794.pub2 [PubMed 21328309]
  192. Singh S, Facciorusso A, Dulai PS, Jairath V, Sandborn WJ. Comparative risk of serious infections with biologic and/or immunosuppressive therapy in patients with inflammatory bowel diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2020;18(1):69-81.e3. doi:10.1016/j.cgh.2019.02.044 [PubMed 30876964]
  193. Solomon DH, Reed GW, Kremer JM, et al. Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol. 2015;67(6):1449-1455. doi:10.1002/art.39098 [PubMed 25776112]
  194. Sridhar S, Maltz RM, Boyle B, Kim SC. Dermatological manifestations in pediatric patients with inflammatory bowel diseases on anti-TNF therapy. Inflamm Bowel Dis. 2018;24(9):2086-2092. doi:10.1093/ibd/izy112 [PubMed 29718343]
  195. Steenholdt C, Svenson M, Bendtzen K, Thomsen OØ, Brynskov J, Ainsworth MA. Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease. J Crohns Colitis. 2012;6(1):108-111. doi:10.1016/j.crohns.2011.08.001 [PubMed 22261535]
  196. Steenholdt C, Svenson M, Bendtzen K, Thomsen OØ, Brynskov J, Ainsworth MA. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2011;34(1):51-58. doi:10.1111/j.1365-2036.2011.04682.x [PubMed 21535447]
  197. Strangfeld A, Eveslage M, Schneider M, et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis. 2011;70(11):1914-1920. doi:10.1136/ard.2011.151043 [PubMed 21791449]
  198. Strangfeld A, Hierse F, Rau R, et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther. 2010;12(1):R5. doi:10.1186/ar2904 [PubMed 20064207]
  199. Sumida K, Ubara Y, Suwabe T, et al. Adalimumab treatment in patients with rheumatoid arthritis with renal insufficiency. Arthritis Care Res (Hoboken). 2013;65(3):471-475. doi:10.1002/acr.21800 [PubMed 22807318]
  200. Sweiss NJ, Noth I, Mirsaeidi M, et al. Efficacy results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(1):46-54. [PubMed 24751453]
  201. Taylor TRP, Galloway J, Davies R, Hyrich K, Dobson R. Demyelinating events following initiation of anti-TNFα therapy in the British Society for Rheumatology Biologics Registry in Rheumatoid Arthritis. Neurol Neuroimmunol Neuroinflamm. 2021;8(3):e992. doi:10.1212/NXI.0000000000000992 [PubMed 33863839]
  202. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560-1599. doi:10.1002/hep.29800 [PubMed 29405329]
  203. Thorne JE. Uveitis: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com. Accessed May 24, 2021.
  204. Titos Arcos JC, Hallal H, Robles M, Andrade RJ. Recurrent hepatotoxicity associated with etanercept and adalimumab but not with infliximab in a patient with rheumatoid arthritis. Rev Esp Enferm Dig. 2012;104(5):282-284. doi:10.4321/s1130-01082012000500014 [PubMed 22662786]
  205. Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of paediatric ulcerative colitis, part 1: ambulatory care-an evidence-based guideline from European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018;67(2):257-291. [PubMed 30044357]
  206. Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000 [PubMed 20000886]
  207. van Rheenen PF, Aloi M, Assa A, et al. The medical management of paediatric Crohn's disease: an ECCO-ESPGHAN guideline update. J Crohns Colitis. Published online October 7, 2020. [PubMed 33026087]
  208. Vermeire S, Noman M, Van Assche G, et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology. 2003;125(1):32-39. doi:10.1016/s0016-5085(03)00701-7 [PubMed 12851868]
  209. Wagner UG, Koetz K, Weyand CM, Goronzy JJ. Perturbation of the T cell repertoire in rheumatoid arthritis. Proc Natl Acad Sci U S A. 1998;95(24):14447-14452. doi:10.1073/pnas.95.24.14447 [PubMed 9826720]
  210. Ward MM, Deodhar A, Gensler LS, et al. 2019 update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Care Res (Hoboken). 2019;71(10):1285-1299. doi:10.1002/acr.24025 [PubMed 31436026]
  211. Weizman AV, Nguyen GC, Seow CH, et al. Appropriateness of biologics in the management of Crohn's disease using RAND/UCLA appropriateness methodology. Inflamm Bowel Dis. 2019;25(2):328-335. doi: 10.1093/ibd/izy333. [PubMed 30346529]
  212. Williams EL, Gadola S, Edwards CJ. Anti-TNF-induced lupus. Rheumatology (Oxford). 2009;48(7):716-720. doi:10.1093/rheumatology/kep080 [PubMed 19416947]
  213. Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum. 2006;54(2):628-634. doi:10.1002/art.21568 [PubMed 16447241]
  214. Yanai H, Shuster D, Calabrese E, Mlynarsky L, Tumuluri S, Cohen RD. The incidence and predictors of lupus-like reaction in patients with IBD treated with anti-TNF therapies. Inflamm Bowel Dis. 2013;19(13):2778-2786. doi:10.1097/01.MIB.0000435435.91988.b6 [PubMed 24185311]
  215. Yuflyma (adalimumab) [prescribing information]. Jersey City, NJ: Celltrion USA Inc; September 2023.
  216. Yuflyma (adalimumab) [product monograph]. Toronto, Ontario, Canada: Celltrion Healthcare Canada Limited; December 2021.
  217. Yusimry (adalimumab-aqvh) [prescribing information]. Redwood City, CA: Coherus BioSciences Inc; September 2023.
Topic 13077 Version 455.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟